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Abstract  26 
Enterobacteriaceae producing carbapenemases, such as KPC or metallo-β-27 
lactamases, have emerged on several continents. Phenotypic tests are urgently needed 28 
for their rapid and accurate detection. A novel and fast flow cytometry test was 29 
developed in order to identify carbapenemase production by Enterobacteriaceae and to 30 
discriminate between the different types of carbapenemases belonging to Ambler 31 
molecular classes A, B, and D. It is based upon the comparison of meropenem 32 
antimicrobial activity alone and coupled with different carbapemase inhibitors 33 
(aminophenylboronic acid and EDTA), assessed by flow cytometry. Decreased 34 
susceptibility to carbapenems caused by either ESBL or AmpC enzymes combined with 35 
decreased permeability was also detected using temocillin and cloxacillin, overcoming 36 
the false positive results obtained with phenotypic carbapenemase detection tests. The 37 
test was applied directly to 60 bacterial colonies, half of them carbapenemases 38 
producers (KPC, VIM, IMP, NDM, IMI, GIM, OXA-48-like, and KPC plus VIM). The 39 
test yielded sensitivity and specificity of 100%, distinguished accurately between 40 
several different mechanisms mediating reduced susceptibility to carbapenems in 41 
Enterobacteriaceae.  It represents a convenient and reliable phenotypical approach for 42 
detection and characterization of different carbapenemases with a time-to-results of 2 43 
hours versus 24 hours of classic methods. 44 
 45 
 46 
 47 
 48 
 49 
 50 
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Introduction 51 
In the last decade, the prevalence of resistance to β-lactam antibiotics mediated 52 
by β-lactamases has increased at an alarming rate, especially among Enterobacteriaceae 53 
(1); firstly, because of the spread of extended spectrum β-lactamases (ESBL) and more 54 
recently due to carbapenemases, which are enzymes able to hydrolyze carbapenems. 55 
These enzymes have also spread rapidly throughout the world (2), being an alarming 56 
problem in some countries, especially in Greece and India (3). In 2015, 13/38 countries 57 
reported inter-regional spread of or an endemic situation for carbapenemase-producing 58 
Enterobacteriaceae (CPE), compared with 6/38 in 2013. Only three countries replied 59 
that they had not identified one single case of CPE (4). Carbapenemases include Ambler 60 
class A (such as Klebsiella pneumoniae carbapenemase, KPC), Ambler class B 61 
(metallo-β-lactamases, MBL, such as VIM-type, IMP-type, NDM-type) and Ambler 62 
class D (OXA-48-types, such as OXA-181) enzymes (Table 1). Invasive infections with 63 
CPE are associated with high morbidity and mortality (5, 6). Carbapenemases may 64 
confer resistance to virtually all β-lactams, and are readily transferable. Additional, CPE 65 
frequently possess resistance mechanisms to a wide-range of antimicrobial agents, since 66 
such enzymes hydrolyze penicillins, in most cases cephalosporins, and to various 67 
degrees carbapenems and monobactams (the latter are not hydrolyzed by metallo-β-68 
lactamases). Accurate detection of CPE is relevant at individual patient not only due to 69 
the impact on antibiotic therapy but also for infection control purposes, especially in 70 
outbreak settings. The European Comittee of Antimicrobial Susceptibility Testing 71 
(EUCAST) recently developed guidelines for carbapenemase detection in 72 
Enterobaceriaceae isolates (7, 8). These recommendations must be adopted whenever 73 
decreased susceptibility to imipenem, meropenem and/or ertapenem is detected, 74 
meaning Minimal Inhibitory Concentration (MIC) values >1, >0.125 and >0.125 mg/L, 75 
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respectively; values below the clinical breakpoints for susceptible phenotype. In the 76 
most recently recommendations (8), imipenem was not considered and meropenem is 77 
the carbapenem that offers the best compromise between sensitivity and specificity in 78 
terms of detecting carbapenemase-producers (9). However, it usually requires 48 hours 79 
after sample collection to determine the MIC value and an additional 18-24 hours to 80 
confirm the presence of carbapenemase. Combination disk test is the unique most 81 
convenient phenotypic method to discriminate different carbapenemases (10-12). In 82 
brief, disks or tablets containing meropenem without and with various inhibitors such as 83 
aminophenyl boronic acid (APBA) as a class A inhibitor and ethylenediaminetetraacetic 84 
acid (EDTA) as a class B inhibitor are used. No inhibitor to OXA-48-type enzymes was 85 
included in the phenotypic panels.  However, these enzymes confer high-level 86 
resistance to temocillin (12). Decreased susceptibility of Enterobacteriaceae to 87 
carbapenems may be also caused by either the production extended spectrum β-88 
lactamases (ESBL) or AmpC β-lactamases coupled with decreased permeability due to 89 
alteration or down-regulation of porins (13). Cloxacillin, which inhibits AmpC β-90 
lactamases, should be added to the test in order to differentiate between AmpC 91 
hyperproduction plus porin loss and carbapenemase-production. Figure 1 represents an 92 
algorithm for interpretation of results with β-lactamases inhibitors recommended by 93 
EUCAST. The main disadvantage of such procedure is that it requires a long incubation 94 
period (18-24 hours), since it is based on growth in presence of the drugs. The same 95 
drawback is appointed to Etest KPC and MBL strips, which associate a carbapenem 96 
with boronic acid or EDTA, respectively (14). A possible alternative is the carbapenem 97 
inactivation method (i.e. CIM-test), which has had variable performance in different 98 
studies and requires at least 18 hours to the result (15). The market available 99 
chromogenic culture media although easy to perform are also growth dependent (16). 100 
5 
 
More recently, different biochemical test such as Carba NP was described to detect 101 
carbapenemase production (17, 18); it seems to be rapid (<2h), sensitive and specific 102 
although cumbersome and expensive and a discrimination among carbapenemase-types 103 
is not possible. MALDI-TOF MS, recently introduced in the laboratory routine, seems 104 
promising in order to detect antibiotic modifications due to degradation by enzymes, 105 
including carbapenemases (19, 20). A new immunochromatographic lateral flow assay 106 
is available for direct identification OXA-48-like enzymes and KPC, but its robustness 107 
has not been evaluated so far (21). Molecular identification of carbapenemase genes 108 
(22, 23) is another possibility but, besides the several genes that must be searched and 109 
high associated costs, it can result in false negatives when mutations or new genes 110 
emerge. 111 
 Flow cytometry (FC) represents an accurate and fast approach for the analysis of 112 
cell architecture and its functional parameters, with considerable advantages over 113 
conventional methods (24). Similar to ESBL detection by FC (25), a novel protocol for 114 
carbapenemase detection, with time-to-results within 2 hours, was hereby developed 115 
and evaluated, using a comprehensive set of phenotypically and molecularly well-116 
characterized strains. 117 
 118 
Results 119 
An increase (of at least twice) in fluorescence intensity, meaning cell lesion, in 120 
the presence of inhibitors, when compared with the intensity in the presence of 121 
meropenem alone, was observed with APBA for all KPC, corresponding to class A 122 
carbapenemases. All VIM, IMP, NDM, IMI and GIM showed an increase in intensity of 123 
fluorescence when cells were treated with meropenem associated with EDTA, 124 
corresponding to class B carbapenemases. Strains with both KPC and MBL enzymes 125 
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had an increase in intensity of fluorescence when cells were treated with meropenem 126 
associated only with APBA plus EDTA. For class D carbapenemases no increase was 127 
observed however, they were resistant to temocillin; the fluorescence intensity of cells 128 
exposed to temocillin was similar to non-exposed cells. For AmpC associated with 129 
porin loss, the increase in cells intensity of fluorescence was observed with APBA but 130 
also with cloxacillin. In case of ESBL associated with porin loss no increase in intensity 131 
of fluorescence was observed; such strains were susceptible to temocillin, increasing 132 
fluorescence intensity of cells exposed to this drug. In Figure 2 a graphic showing the 133 
median values of intensity of fluorescence for each type of carbapenemases and for a 134 
group of non-producers is represented. A typical example of the different types 135 
concerning flow cytometry data are shown in figure 2. This FC kit combines excellent 136 
sensitivity (100%), specificity (100%) and short time to result. 137 
 138 
Discussion 139 
Carbapenemases are considered to be of high epidemiological importance, 140 
particularly when they confer decreased susceptibility to carbapenems. It is high 141 
recommended the application in clinical routine of phenotypic methods for detection of 142 
carbapenemases. The main categories of methods available have disadvantages 143 
encouraging the development of novel rapid methods. The rapid phenotypic tests been 144 
so far developed have limitations. The colorimetric tests (CarbaNP test, Blue-Carba test 145 
or β CARBA test™) only detect the carbapenemase production not allowing the 146 
distinction among the different classes and lack sensitivity for Enterobacteriaceae 147 
producing OXA-48 (17, 26, 27). Similar disadvantages are also appointed to MALDI-148 
TOF technology for detection of carbapenem hydrolysis (19, 20). A new 149 
immunochromatographic lateral flow assay although promising its robustness has not 150 
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been evaluated so far (21, 28). FC already demonstrated to be an excellent tool in 151 
microbiology (24), overcoming the methods in use in routine clinical laboratories 152 
depending on growth; it gives a quicker and much more informative antimicrobial 153 
phenotype. The present work described the performance of a new method based upon 154 
FC that enables the fast determination of carbapenemases. The test exhibited 100% of 155 
sensitivity and specificity directly from bacterial colonies.  It has the potential to be 156 
applied directly from blood cultures, saving extra 24 hours for bacterial isolation after 157 
sample collection. Indeed, a novel FASTinov
®
 kit for antimicrobial susceptibility 158 
testing (AST) of Gram negative bacilli directly on positive blood culture was already 159 
tested and exhibited an overall agreement of 98% with the reference microdilution 160 
method (29). Moreover, the impact of the use of a rapid AST in clinical routine was 161 
evaluated resulting in a reduced in hospital length of stay, lower consumption of 162 
antibiotics and in ultimately case improved infection control. Recently, new data was 163 
obtained with the use of this methodology directly from blood culture. The kit was able 164 
to distinct the different types of carbapenemases (30).  165 
The method although currently present as a semi-automated method, since it has 166 
dedicated software, it could be fully automatized. The estimated costs for this new 167 
method are rather low, around two and half euros per microorganism and the FC 168 
equipment is frequently found in most hematology/immunology laboratories. The early 169 
detection of carbapenemases could have a real impact on outbreaks as well as in 170 
antibiotic therapy (31, 32). The improvement in detection and surveillance of CPE 171 
might contribute for their epidemiological control. 172 
 173 
 174 
 175 
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Material and Methods 176 
Bacterial strains 177 
A panel of 30 carbapenemase-producing Enterobacteriaceae strains was used in this 178 
study: KPC (8), VIM (7), IMP (1), NDM (4), IMI (1), GIM (1), OXA-48-like (6), and 179 
KPC plus VIM (2). As non-carbapenemase producers, 30 Enterobacteriaceae strains, 180 
including several strains that give false positive results on phenotypic tests (9), like 181 
ESBL or AmpC producers coupled to impermeability, were included.  182 
Inoculum preparation 183 
Bacterial suspensions, of the 60 strains described above, were prepared in Brain-Heart 184 
medium (Merck) with approximately 10
6
 cells/mL at initial log phase, (O.D.600nm ≥ 0.2, 185 
which takes approximately 1.5 hours).  186 
Flow cytometric kit inoculation  187 
A novel flow cytometric kit for carbapenemase detection (provided by FASTinov Ltd, 188 
Porto, Portugal) was used. Briefly, bacterial cells obtained directly from colonies were 189 
incubated with meropenem (2 and 8 µg/mL) with and without the inhibitors APBA (2.5 190 
and 5 mM), EDTA (6.25 and 12.5 mM), APBA plus EDTA (2.5 plus 6.25 and 5 plus 191 
12.5 mM) and cloxacillin (250 and 500 µg/mL). Temocillin (Eumedica S.A., Brussels, 192 
Belgium) alone, at 32 and 64 µg/mL was also included. The kit fluorochrome dye was 193 
disposed in all tubes. Cells were incubated for 1 hour at 37ºC and analyzed in a flow 194 
cytometer apparatus. 195 
Flow cytometry analysis 196 
Bacteria cells after exposure to antimicrobial treatments were analysed at a 197 
FACSCalibur flow cytometer (Becton Dickinson). The intensity of fluorescence of cells 198 
treated with meropenem alone was compared with those exposed to meropenem plus 199 
inhibitors.  200 
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TABLE 1. Classification of carbapenemases according to Ambler molecular classes.  350 
 351 
Molecular class Enzyme 
A KPC, NMC, IMI, SME, GES 
B IMP, VIM, GIM, SPM, NDM 
D OXA 
 352 
 353 
 354 
 355 
 356 
 357 
 358 
 359 
 360 
 361 
 362 
 363 
 364 
 365 
 366 
 367 
 368 
 369 
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Figure 1. Algorithm for interpretation of phenotypic tests for carbapenemase detection 370 
with β-lactamases inhibitors. APBA, aminophenylboronic acid; PBA, phenyl boronic 371 
acid; EDTA, ethylenediaminetetraacetic acid; DPA, dipicolinic acid; MBL, metallo-β-372 
lactamase; KPC, Klebsiella pneumoniae carbapenemase. *MIC above the 373 
epidemiological cut-off values defined by EUCAST.  374 
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Figure 2. Graphic representing the mean of stain indexs of each group of strains: KPC 413 
carbapenemases, MBL carbapenemases, OXA-48-like carbapenemases and non-414 
producers, being the stain index the ratio between the intensity of fluorescence at FL1 of 415 
cells treated with the meropenem plus the inhibitor(s) and cells treated only with 416 
meropenem. Concerning temocillin the stain index is the ratio between cells treated with 417 
temocillin and cells no treated. For each strain the combination both drugs at lower 418 
concentration each was evident an increase in intensity of fluorescence was choose to 419 
performed the calculation.  420 
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Figure 3. Representative histograms obtained by flow cytometry for different type of 441 
carbapenemases. For each strain (Klebsiella pneumoniae KPC-2, Enterobacter cloacae 442 
VIM-4 and K. pneumoniae OXA-48) it is represented the cells non-exposed to drugs, 443 
cells exposed to meropenem 8 µg/mL and with the inhibitors APBA 5 mM, EDTA 12,5 444 
mM, APBA 5 mM plus EDTA 12,5 mM  or cloxacillin 500 µg/mL and cells exposed to 445 
temocillin 32 µg/mL. IF, intensity of fluorescence.  446 
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guidelines may be of assistance.
(i) Papers which describe the use of antimicrobial agents
as tools for elucidating the basic biological processes of bac-
teria are considered more appropriate for the Journal of
Bacteriology®.
(ii) Manuscripts that (a) describe the use of antimicrobial or
antiparasitic agents as tools in the isolation, identification, or
epidemiology of microorganisms associated with disease; (b)
are concerned with quality control procedures for diffusion,
elution, or dilution tests for determining susceptibilities to an-
timicrobial agents in clinical laboratories; and (c) deal with
applications of commercially prepared tests or kits to assays
performed in clinical laboratories to measure the activities of
established antimicrobial agents or their concentrations in
body fluids are considered more appropriate for the Journal
of Clinical Microbiology®. Manuscripts concerned with the de-
velopment or modification of assay methods (e.g., high-
throughput screening techniques) and validation of their sen-
sitivity and specificity with a sufficiently large number of
determinations or compounds are considered appropriate for
AAC. Assay methods for the detection and characterization of
concentrations of antimicrobials in sera or other body fluids
are not within AAC’s scope.
(iii) Susceptibility studies describing novel findings or test-
ing new agents, and those with broad geographic reach, de-
tailed mechanistic analysis, and important epidemiological
implications, will be given higher priority than those testing
isolates from local regions, with limited analysis, or with mod-
est numbers of tested species or microorganisms. Single-center
epidemiological studies (such as those defining risk factors for
resistant infections) for which results are neither novel nor
generalizable beyond the local environment are not appropri-
ate for AAC.
(iv) Manuscripts describing new or novel methods or im-
provements in media and culture conditions will not be con-
sidered for publication in AAC unless these methods are ap-
plied to the study of problems related to the production or
activity of antimicrobial agents. Such manuscripts are more
appropriate for Applied and Environmental Microbiology® or
the Journal of Clinical Microbiology®.
(v) Manuscripts dealing with properties of unpurified nat-
ural products, with entities that are primarily antitumor
agents, or with immunomodulatory agents that are not anti-
microbial agents are not appropriate for AAC. In addition,
papers addressing photodynamic therapy are no longer appro-
priate for AAC.
(vi) Manuscripts dealing with novel small molecular antimi-
crobials must provide at least some data showing that the pro-
posed new agents or scaffolds have the potential to become
therapeutic agents. Appropriate demonstrations will vary but
generally should be some combination of data on physical
properties (solubility, protein binding, log P [logarithm of the
ratio of the concentrations of un-ionized solutes in solvents]),
pharmacological properties (Caco2 predictions of bioavail-
ability, pharmacokinetics in an animal species), or tolerability
(mammalian cell toxicity, likelihood of hepatic metabolism,
potential for receptor interactions, potential for human ERG
liability). Studies focusing on detailed mechanisms of cellular
toxicity that lack whole-organ or animal studies are more ap-
propriate for Molecular and Cellular Biology than for AAC. Ini-
tial presentations of compounds are not expected to address all
these areas but rather to show an appropriate initial subset. For
example, the first publication of a novel compound or com-
pound series might address selected physical properties plus
mammalian cell toxicity. Subsequent publications are ex-
pected to add progressively to the proof of the agent’s thera-
peutic potential.
(vii) Biochemical analyses for -lactamases that determine
kinetic parameters (e.g., Km, kcat) must be performed on puri-
fied enzyme preparations. The enzyme must be in its native
form, without any leader sequences or fusions used for purifi-
cation (e.g., His tag). Enzymes for which the His tag has been
removed can be considered native enzymes. The determina-
tion of relative rates of hydrolysis may be performed on crude
extracts.
(viii) Authors of papers describing enzymological studies
should review the standards of the STRENDA Commission for
information required for adequate description of experimental
conditions and for reporting enzyme activity data (http://www
.beilstein-institut.de/en/projects/strenda/guidelines).
(ix) A manuscript limited to the nucleic acid sequence of a
gene encoding an antibiotic target, receptor, or resistance
mechanism may be submitted as a Short-Form paper (see
“Short-Form Papers”) or a New-Data Letter to the Editor (see
“Letters to the Editor”), depending on its length. Formatting
instructions for nucleic acid sequences are given below (see
“Presentation of Nucleic Acid Sequences”). Repetition of se-
quences already in a database should be avoided.
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Questions about these guidelines may be directed to the ed-
itor in chief of the journal being considered.
If transfer to another ASM journal is recommended by an
editor, the corresponding author will be contacted.
Note that a manuscript rejected by one ASM journal on
scientific grounds or on the basis of its general suitability for
publication is considered rejected by all other ASM journals.
EDITORIAL POLICY AND ETHICAL GUIDELINES
As a member of the Committee on Publication Ethics
(COPE), ASM adheres to COPE’s Best Practice Guidelines and
expects authors to observe the high standards of publication
ethics set out by COPE. ASM requirements for submitted man-
uscripts are consistent with the Recommendations for the
Conduct, Reporting, Editing, and Publication of Scholarly
Work in Medical Journals, as last updated by the International
Committee of Medical Journal Editors in December 2014
(http://www.icmje.org/).
Authors are expected to adhere to the highest ethical stan-
dards. The following sections of these Instructions include de-
tailed information about ASM’s ethical standards. Failure to
comply with the policies described in these Instructions may
result in a letter of reprimand, a suspension of publishing priv-
ileges in ASM journals, and/or notification of the authors’ in-
stitutions. Authors employed by companies whose policies do
not permit them to comply with ASM policies may be sanc-
tioned as individuals and/or ASM may refuse to consider man-
uscripts having authors from such companies.
Use of Microbiological Information
The Council on Microbial Sciences (COMS) of the Ameri-
can Society for Microbiology affirms the long-standing posi-
tion of the Society that microbiologists will work for the proper
and beneficent application of science and will call to the atten-
tion of the public or the appropriate authorities misuses of
microbiology or of information derived from microbiology.
ASM members are obligated to discourage any use of microbi-
ology contrary to the welfare of humankind, including the use
of microbes as biological weapons. Bioterrorism violates the
fundamental principles expressed in the Code of Ethics of the
Society and is abhorrent to ASM and its members.
ASM recognizes that there are valid concerns regarding the
publication of information in scientific journals that could be
put to inappropriate use as described in the COMS resolution
mentioned above. Members of the ASM Journals Board will
evaluate the rare manuscript that might raise such issues
during the review process. However, as indicated elsewhere in
these Instructions, primary-research articles must contain suf-
ficient detail, and material/information must be made avail-
able, to permit the work to be repeated by others. Supply of
materials should be in accordance with laws and regulations
governing the shipment, transfer, possession, and use of bio-
logical materials and must be for legitimate, bona fide research
needs. We ask that authors pay particular attention to the
NSAR Select Agent/Toxin list on the CDC website https://www
.selectagents.gov/index.html and the U.S. Government Policy
for Oversight of Life Sciences Dual Use Research of Concern
(March 2012; http://www.phe.gov/s3/dualuse/Documents/us-
policy-durc-032812.pdf).
Use of Human Subjects or Animals in Research
Authors of manuscripts describing research involving hu-
man subjects or animal experimentation must obtain review
and approval (or review and waiver) from their Institutional
Review Board (IRB) or Institutional Animal Care and Use
Committee (IACUC), as appropriate, prior to manuscript sub-
mission. Authors of manuscripts that describe multisite re-
search must obtain approval from each institution’s IRB or
IACUC, as appropriate. Documentation of IRB or IACUC
status must be made available upon request. In the event
that institutional review boards or committees do not exist,
the authors must ensure that their research is carried
out in accordance with the Declaration of Helsinki, as re-
vised in 2013 (https://jamanetwork.com/journals/jama
/fullarticle/1760318), and/or the “International Guiding
Principles for Biomedical Research Involving Animals,” as
revised by the International Council for Laboratory Animal
Science (ICLAS) and the Councils for International Orga-
nizations of Medical Sciences (CIOMS) in 2012. A state-
ment of IRB or IACUC approval or waiver (and reason for
waiver) or a statement of adherence to the Declaration of
Helsinki and/or Guiding Principles must be included in the
Materials and Methods section. The sex of research subjects
and animals, and of materials derived directly from them
(e.g., primary cell lines and clinical samples), should be in-
cluded in the Materials and Methods section or Results sec-
tion if these data are available.
Patient Identiﬁcation
Informed consent is not needed if the patient cannot be
identified from any material in a manuscript. In the absence of
informed consent, identifying details, such as patient initials,
specific dates, specific geographic exposures, or other identify-
ing features (including body features in figures), should be
omitted, but this must not alter the scientific meaning. Impor-
tant information that is relevant to the scientific meaning
should be stated so that the patient cannot be identified, e.g., by
stating a season instead of a date or a region instead of a city. If
a patient can be identified from the material in a manuscript,
all efforts should be made to obtain informed consent to pub-
lish from patients or parents/legal guardians of minors. In-
formed consent requires that the patient have the opportunity
to see the manuscript prior to submission. The written consent
must state either that the patient has seen the complete manu-
script or that the patient declines to do so. Patient consent
should be archived with the authors and be available upon
request. A statement attesting the receipt and archiving of writ-
ten patient consent should be included in the published article.
Publishing Ethics
Authorship. ASM journals follow the criteria for authorship
as outlined in the International Committee of Medical Journal
Editors (ICMJE) Recommendations for the Conduct, Reporting,
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Editing, and Publication of Scholarly Work in Medical Journals
(“Defining the Role of Authors and Contributors”). Briefly, an
author is one who makes a substantial contribution to the design,
execution, and/or analysis and interpretation of experiments in
addition to drafting, revising, and/or approving the initial sub-
mission and any subsequent versions of the article. All authors of
a manuscript must have agreed to its submission and are respon-
sible for appropriate portions of its content. Submission of a paper
before all coauthors have read and approved it is considered an
ethical violation.
Author contribution statements. As explained in the
ICMJE recommendations, all persons designated as authors
should qualify for authorship, and all those who qualify should be
listed. ASM encourages transparency in authorship by publishing
author contribution statements. Authors are strongly encouraged
to include such statements in the Acknowledgments section.
Corresponding author. The corresponding author takes
primary responsibility for communicating with the journal
and coauthors throughout the submission, peer review, and
publication processes. The corresponding author is responsi-
ble for ensuring that all coauthors have read and approved
submissions, including appropriate citations, acknowledg-
ments, and byline order. Additionally, the corresponding au-
thor and the study’s primary investigator(s), if different, are
required to have examined the raw data represented in the
manuscript, affirm that such representations accurately reflect
the original data, and ensure that the original data are pre-
served and retrievable.
Consortium authorship. A study group, surveillance team,
working group, consortium, or the like (e.g., the Active Bacte-
rial Core Surveillance Team) may be listed as a coauthor in the
byline if its contributing members satisfy the requirements for
authorship and accountability as described in these Instruc-
tions. The names (and institutional affiliations, if desired) of
the contributing members only may be given as a separate
paragraph in the Acknowledgments section. If the contribut-
ing members of the group associated with the work do not
fulfill the criteria of substantial contribution to and responsi-
bility for the paper, the group may not be listed in the author
byline. Instead, it and the names of its contributing members
may be listed in the Acknowledgments section.
Professionalwriters. “Ghost authorship” is not permitted by
ASM. Professional writers should be mentioned in the Acknowl-
edgments section rather than be included in the byline. To avoid
perceived conflicts of interest, writer affiliations and specific con-
tributions (for example, writing assistance, technical editing, lan-
guage editing, or proofreading) must be disclosed.
Nonauthor contributions. Contributions from individu-
als who do not meet the ICMJE criteria for authorship should
be acknowledged in the Acknowledgments section. Those that
provided assistance, e.g., supplied strains or reagents or cri-
tiqued the paper, should not be listed as authors. Acquisition of
funding, data collection, or general supervision of the research
group does not qualify a person or persons for authorship. As
mentioned above, professional writers do not meet authorship
criteria and should be mentioned in the Acknowledgments
section. Specific contributions for each nonauthor contributor
should be included.
Byline order and changes. All authors must agree to the
order in which their names are listed in the byline. Statements
regarding equal contributions by two or more authors (e.g.,
“C.J. and Y.S. contributed equally to . . .”) are permitted as
footnotes to bylines and must be agreed to by all of the authors.
A change in authorship (order of listing, addition or deletion of
a name, or corresponding author designation) after submis-
sion of the manuscript will be implemented only after receipt
of signed statements of agreement from all parties involved.
Authorship disputes. Disputes about authorship may delay
or prevent review and/or publication of the manuscript. Should
the individuals involved be unable to reach an accord, review
and/or publication of the manuscript can proceed only after the
matter is investigated and resolved by the authors’ institution(s)
and an official report provided to ASM. ASM does not itself in-
vestigate or attempt to resolve authorship disputes but will follow
institutional recommendations, as appropriate.
ORCID. ASM Journals is a member of Open Researcher and
Contributor ID (ORCID) and publishes author ORCID num-
bers in articles. ORCID is an open, nonprofit, community-driven
effort to create and maintain a registry of unique researcher
identifiers; it is a transparent method of linking research activ-
ities and output to these identifiers. In the eJournalPress (eJP)
submission system, authors are encouraged to use or create an
ORCID number, which can be linked to manuscripts and pub-
lications for which a researcher serves as an author. This can be
helpful in distinguishing authors with common names. Addi-
tional information about ORCID is available on ORCID’s
website.
Plagiarism. Misappropriating another person’s intellec-
tual property constitutes plagiarism. This includes copying
sentences or paragraphs verbatim (or almost verbatim)
from someone else’s work, even if the original work is cited
in the references. The NIH Office of Research Integrity publi-
cation “Avoiding Plagiarism, Self-Plagiarism, and Other Ques-
tionable Writing Practices: a Guide to Ethical Writing” (https:
//ori.hhs.gov/avoiding-plagiarism-self-plagiarism-and-other-
questionable-writing-practices-guide-ethical-writing) can
help authors identify questionable writing practices.
Plagiarism is not limited to the text; it can involve any part of
the manuscript, including figures and tables, in which material is
copied from another publication without permission and attribu-
tion. An author may not reuse his or her own previously pub-
lished work without attribution; this is considered text recycling
(also known as self-plagiarism).
ASM has incorporated plagiarism detection software into its
online submission and peer review system in order to help editors
verify the originality of submitted manuscripts. Selected manu-
scripts are scanned and compared with databases. If plagiarism is
detected, COPE guidelines on plagiarism will be followed.
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Image manipulation. Submitted figures must reflect origi-
nal data. Please refer to the “Image manipulation” section in
Illustrations and Tables for an overview of permissible manip-
ulations, unacceptable adjustments, and required information
to be disclosed in the figure legends of images.
ASM applies forensic imaging tools to screen selected man-
uscripts for inappropriate manipulation of figures. If unac-
knowledged and/or inappropriate image manipulations are
detected, the matter will be referred to the journal’s ethics
panel for consideration.
Fabrication, manipulation, and falsification of data. As a
member of the Committee on Publication Ethics (COPE), ASM en-
courages authors to consult COPE’s “Code of Conduct and Best
Practice Guidelines for Journal Editors” (https://publicationethics.
org/files/Code_of_conduct_for_journal_editors_0.pdf). Fabri-
cation, manipulation, and falsification of data constitute
misconduct. As defined by the U.S. Department of Health
and Human Services, fabrication is “making up data or re-
sults and recording or reporting them,” and falsification is
“manipulating research materials, equipment, or processes,
or changing or omitting data or results such that the re-
search is not accurately represented in the research record”
(42 Code of Federal Regulations, §93.103). All sources and
methods used to obtain and analyze data, including any
electronic preprocessing, should be fully disclosed; detailed
explanations should be provided for any exclusions.
Primary publication. Manuscripts submitted to the jour-
nal must represent reports of original research, and the original
data must be available for review by the editor if necessary. By
submitting a manuscript to the journal, the authors guarantee
that they have the authority to publish the work and that the
manuscript, or one with substantially the same content, was
not published previously, is not being considered or pub-
lished elsewhere, and was not rejected on scientific grounds
by another ASM journal. It is incumbent upon the author to
acknowledge any prior publication, including his/her own ar-
ticles, of the data contained in a manuscript submitted to an
ASM journal. A copy of the relevant work should be submitted
with the paper as supplemental material not for publication.
Whether the material constitutes the substance of a paper and
therefore renders the manuscript unacceptable for publication
is an editorial decision.
In the event that the authors’ previously published figures
and/or data are included in a submitted manuscript, it is in-
cumbent upon the corresponding author to (i) identify the
duplicated material and acknowledge the source on the sub-
mission form, (ii) obtain permission from the original pub-
lisher (i.e., copyright owner), (iii) acknowledge the duplication
in the figure legend, and (iv) cite the original article.
A paper is not acceptable for submission to an ASM journal
if it, or its substance, has been made publicly available in the
following:
• A serial, periodical, or book
• A conference report or symposium proceedings
• A technical bulletin or company white paper
• A public website (see “Preprint policy”)
• Any other retrievable source
The following do not preclude submission to, or publication
by, an ASM journal:
• Posting of a method/protocol on a public website
• Posting of a limited amount of original data on a per-
sonal/university/corporate website or websites of small
collaborative groups working on a problem
• Deposit of unpublished sequence data in a public da-
tabase
• Preliminary disclosures of research findings as meeting
posters, webcast as meeting presentations, or pub-
lished in abstract form as adjuncts to a meeting, e.g.,
part of a program
• Posting of theses and dissertations on a personal/
university-hosted website
Preprint policy. ASM Journals will consider for publication
manuscripts that have been posted in a recognized not-for-
profit preprint archive provided that upon acceptance of the
manuscript for publication, the author is still able to grant
ASM copyright or agree to the terms of an Open Access license
and pay the associated fee. It is the responsibility of authors to
inform the journal at the time of submission if and where their
article has been previously posted, and if the manuscript is
accepted for publication in an ASM journal, authors are re-
quired to update the preprint with a citation to the final pub-
lished article that includes the URL along with a link.
Conﬂict of Interest
All authors are expected to disclose, in the manuscript sub-
mittal letter, any commercial affiliations as well as consultan-
cies, stock or equity interests, and patent-licensing arrange-
ments that could be considered to pose a conflict of interest
regarding the submitted manuscript. (Inclusion of a company
name in the author address lines of the manuscript does not
constitute disclosure.) Details of the disclosure to the editor
will remain confidential. However, it is the responsibility of
authors to provide, in the Acknowledgments section, a general
statement disclosing conflicting interests relevant to the study.
Examples of potentially conflicting interests include relation-
ships, financial or otherwise, that might detract from an au-
thor’s objectivity in presentation of study results and interests
whose value would be enhanced by the results presented. All
funding sources for the project, institutional and corporate,
should be credited in the Acknowledgments section, as de-
scribed below. In addition, if a manuscript concerns a com-
mercial product, the manufacturer’s name must be indicated
in the Materials and Methods section or elsewhere in the text,
as appropriate, in an obvious manner.
Data and Materials
Availability of data and materials. By publishing in the
journal, the authors agree that, subject to requirements or lim-
itations imposed by local and/or U.S. Government laws and
regulations, any materials and data that are reasonably re-
quested by others are available from a publicly accessible col-
lection or will be made available in a timely fashion, at reason-
able cost, and in limited quantities to members of the scientific
Instructions to Authors
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community for noncommercial purposes. Similarly, the au-
thors agree to make available computer programs and/or code,
originating in the authors’ laboratory, that is the only means of
confirming the conclusions reported in the article but that is
not available commercially. The program(s) and suitable doc-
umentation regarding its (their) use may be provided by any of
the following means: (i) as a program transmitted via the In-
ternet, (ii) as an Internet server-based tool, or (iii) as a com-
piled or assembled form on a suitable medium. The authors
guarantee that they have the authority to comply with this
policy either directly or by means of material transfer agree-
ments through the owner. ASM asks authors to assert this in a
“Data availability” paragraph, which should appear at the end
of the Materials and Methods section (or at the end of the text)
of their submitted manuscript.
Data citation. To promote reproducibility, ASM expects
researchers to identify and cite data sets and/or code used in
their experiments and studies. These may be large or complex
data sets that can include, but are not limited to, data from
microarray, genomic, structural, proteomic, or video imaging
analyses.Authors should cite both thedata set repository and
the published article in which the data set and/or code was
originally described. Citations of data should be included in
the reference list with persistent unique identifiers (e.g., active
URLs, accession numbers, etc.). If computer code or software
was created to generate results or interpret data, then a state-
ment to that effect should be included in the “Data availability”
paragraph. For cases in which the software is publicly available
(e.g., FigTree to generate phylogenetic trees), the URL of the soft-
ware informational page should be provided. It is preferred that
authorsuseestablished,publiclyavailabledata type-specificre-
positories. If there is no appropriate repository available, general
publicly available repositories should be used (e.g., Dryad, fig-
share, etc.). Examples of proper data citation are included in the
“References” section of these Instructions to Authors.
Culture deposition. AAC expects authors to deposit
strains used in therapeutic activity assessments and studies of
mechanisms of action, resistance, and cross-resistance in pub-
licly accessible culture collections and to refer to the collections
and strain numbers in the text. Since the authenticity of sub-
cultures of culture collection specimens that are distributed by
individuals cannot be ensured, authors should indicate labo-
ratory strain designations and donor sources as well as original
culture collection identification numbers.
Authentication of cell lines. Cell line misidentification or
contamination can adversely impact the validity of research
findings. Authors should describe the source along with the
date and method used for authentication of any cell lines used
in manuscripts submitted to this journal. Cell lines used less
than 6 months after receipt from a cell bank that performs
authentication do not require reauthentication, but the source
and method of authentication should be reported in the Ma-
terials and Methods section.
Nucleotide and amino acid sequences. Newly determined
nucleotide and/or amino acid sequence data must be deposited
and GenBank/ENA/DDBJ accession numbers must be in-
cluded in the manuscript no later than the modification stage
of the review process. It is expected that the sequence data will
be released to the public no later than the publication (online
posting) date of the accepted manuscript. Authors are encour-
aged to comply with community metadata standards, such as
the “Minimal Information about any (X) Sequence” (MIxS)
checklist (http://gensc.org/projects/mixs-gsc-project/), when
submitting to GenBank, ENA, or DDBJ. The accession num-
bers should be included in a separate paragraph with the
lead-in “Accession number(s)” at the end of the Materials and
Methods section for Research Articles or at the end of the text
for Short-Form papers. If conclusions in a manuscript are
based on the analysis of sequences and a GenBank/ENA/DDBJ
accession number is not provided at the time of the review,
authors should provide the annotated sequence data as supple-
mental material not for publication.
It is expected that, when previously published sequence ac-
cession numbers are cited in a manuscript, the original pub-
lished article(s), as well as a citation of the database where the
accession number is deposited, will be included in the Refer-
ences section.
Authors are also expected to do elementary searches and com-
parisons of nucleotide and amino acid sequences against the se-
quences in standard databases (e.g., GenBank) immediately be-
fore manuscripts are submitted and again at the proof stage.
Analyses should specify the database, and the date of each
analysis should be indicated as, e.g., 6 January 2018. If relevant,
the version of the software used should be specified.
See “Presentation of Nucleic Acid Sequences” for nucleic
acid sequence formatting instructions.
The URLs of the databases mentioned above are as follows:
DNA Data Bank of Japan (DDBJ), http://www.ddbj.nig.ac.jp/;
European Nucleotide Archive (ENA), https://www.ebi.ac.uk
/ena/; and GenBank, National Center for Biotechnology Infor-
mation, https://www.ncbi.nlm.nih.gov/nucleotide.
Proper use of locus tags as systematic identifiers for genes.
To comply with recommendations from the International Nu-
cleotide Sequence Database (INSD) Collaborators and to
avoid conflicts in gene identification, researchers should im-
plement the following two fundamental guidelines as stan-
dards for utilization of locus tags in genome analysis, annota-
tion, submission, reporting, and publication. (i) Locus tag
prefixes are systematic gene identifiers for all of the replicons of
a genome and as such should be associated with a single ge-
nome project submission. (ii) New genome projects must be
registered with the INSD, and new locus tag prefixes must be
assigned in cooperation with the INSD to ensure that they
conform to the agreed-upon criteria.
Structural determinations. Coordinates for new struc-
tures of macromolecules determined by X-ray crystallography
or cryo-electron microscopy must be deposited in the Protein
Data Bank and assigned identification codes must be included
in the manuscript no later than the modification stage of the
review process. It is expected that the coordinates will be re-
leased to the public no later than the publication (online post-
ing) date of the accepted manuscript. Authors are encouraged
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to send coordinates with their original submission, however,
so that reviewers can examine them along with the manuscript.
The accession number(s) should be listed in a separate para-
graph with the lead-in “Accession number(s)” at the end of the
Materials and Methods section for Research Articles or at the
end of the text for Short-Form papers.
The URLs for coordinate deposition are https://deposit-1
.wwpdb.org/deposition/ and http://www.rcsb.org/pdb/home/
home.do#Category-deposit.
Gene expression data. The entire set of supporting microar-
ray, next-generation sequencing, or other high-throughput
functional genomics data must be deposited in the appropriate
public database (e.g., GEO, ArrayExpress, or CIBEX) and the
assigned accession number(s) must be included in the manu-
script no later than the modification stage of the review pro-
cess. It is expected that the data will be released to the public no
later than the publication (online posting) date of the accepted
manuscript. Authors are encouraged to send the relevant data
with their original submission, however, so that reviewers can
examine them along with the manuscript. The accession num-
ber(s) should be listed in a separate paragraph with the lead-in
“Accession number(s)” at the end of the Materials and Meth-
ods section for Research Articles or at the end of the text for
Short-Form papers.
The URLs of the databases mentioned above are as fol-
lows: Gene Expression Omnibus (GEO), https://www
.ncbi.nlm.nih.gov/geo/; ArrayExpress, https://www.ebi.ac
.uk/arrayexpress/; and Center for Information Biology
Gene Expression Database (CIBEX), https://cibex.nig.ac.jp
/data/index.html.
MycoBank. New scientific names of fungi along with key
nomenclatural and descriptive material must be deposited in
MycoBank (http://www.mycobank.org/) and the assigned ac-
cession number(s) must be included in the manuscript no later
than the modification stage of the review process. It is expected
that the data will be released to the public no later than the
publication (online posting) date of the accepted manuscript.
Authors are encouraged to send the relevant data with their
original submission, however, so that reviewers can examine
them along with the manuscript. The accession number(s)
should be listed in a separate paragraph with the lead-in “Ac-
cession number(s)” at the end of the Materials and Methods
section for Research Articles and at the end of the text for
Short-Form papers.
Copyright
For authors who do not opt to publish their papers as open
access, ASM requires the corresponding author to sign a copy-
right transfer agreement on behalf of all the authors.
In the copyright transfer agreement signed by an author,
ASM grants to that author (and coauthors) the right to repub-
lish discrete portions of his/her (their) article in any other pub-
lication (print, CD-ROM, and other electronic forms) of
which he/she is (they are) the author(s) or editor(s), on the
condition that appropriate credit is given to the original ASM
publication. This republication right also extends to posting on
a host computer to which there is access via the Internet. Ex-
cept as indicated below, significant portions of the article may
not be reprinted/posted without ASM’s prior written permis-
sion, however, as this would constitute duplicate publication.
Authors may post their own published articles on their
personal or university-hosted (but not corporate, govern-
ment, or similar) websites without ASM’s prior written per-
mission provided that appropriate credit is given (i.e., the
copyright lines shown at the bottom of the first page of the
PDF version).
Works authored solely by U.S. Government employees are
not subject to copyright protection, so there is no copyright to
be transferred. However, the other provisions of the copyright
transfer agreement, such as author representations of original-
ity and authority to enter into the agreement, apply to U.S.
Government employee authors as well as to other authors.
When funds from the Wellcome Trust, Research Councils
UK, or the Bill and Melinda Gates Foundation are used to pay
an article open access fee, the article will be published under
the Creative Commons Attribution 4.0 International license
(CC BY 4.0) in accordance with the funding organization’s
open access policies. Authors will be required to notify ASM
and complete the Author Warranty and Provisional License to
Publish at the time of submission.
Copyright for supplemental material (see “Supplemental
Material”) remains with the author, but a license permitting
the posting by ASM is included in the article copyright transfer
agreement. If the author of the article is not also the copyright
owner of the supplemental material, the corresponding author
must send to ASM signed permission from the owner that
allows posting of the material, as a supplement to the article, by
ASM. The corresponding author is also responsible for incor-
porating into the supplemental material any copyright notices
required by the owner.
Permissions
The corresponding author is responsible for obtaining per-
mission from both the original author and the original pub-
lisher (i.e., the copyright owner) to reproduce or modify fig-
ures and tables and to reproduce text (in whole or in part) from
previous publications.
Permission(s) must be obtained no later than the modifica-
tion stage. The original signed permission(s) must be identi-
fied as to the relevant item in the ASM manuscript (e.g., “per-
missions for Fig. 1 in AAC00123-18”) and submitted to the
ASM production editor on request. In addition, a statement
indicating that the material is being reprinted with permission
must be included in the relevant figure legend or table footnote
of the manuscript. Reprinted text must be enclosed in quota-
tion marks, and the permission statement must be included as
running text or indicated parenthetically.
It is expected that the authors will provide written assurance
that permission to cite unpublished data or personal commu-
nications has been granted.
For supplemental material intended for posting by ASM (see
“Supplemental Material”), if the authors of the AAC manu-
script are not also the owners of the supplemental material, the
corresponding author must send to ASM signed permission
from the copyright owner that allows posting of the material,
as a supplement to the article, by ASM. The corresponding
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author is also responsible for incorporating in the supplemen-
tal material any copyright notices required by the owner.
Warranties and Exclusions
Articles published in this journal represent the opinions of
the authors and do not necessarily represent the opinions of
ASM. ASM does not warrant the fitness or suitability, for any
purpose, of any methodology, kit, product, or device described or
identified in an article. The use of trade names is for identification
purposes only and does not constitute endorsement by ASM.
SUBMISSION, REVIEW, AND PUBLICATION PROCESSES
Submission Process
All submissions to AAC must be made electronically via the
eJournalPress (eJP) online submission and peer review system
at the following URL: https://aac.msubmit.net/cgi-bin/main
.plex. (E-mailed submissions will not be accepted.) First-time
users must create an Author account, which may be used for
submitting to all ASM journals. Instructions for creating an
Author account are available at the above URL via the “help for
authors” link, and step-by-step instructions for submitting a
manuscript via eJP are also available through the same link on
the log-in screen or on the account holder’s Home page. Infor-
mation on file types acceptable for electronic submission can
be found under the Files heading in the help for authors screen.
Review Process
All manuscripts are considered to be confidential and are
reviewed by the editors, members of the editorial board, or
qualified ad hoc reviewers. To expedite the review process, au-
thors must recommend at least three reviewers who have ex-
pertise in the field, who are not members of their institution(s),
who have not recently been associated with their laborato-
ry(ies), and who could not otherwise be considered to pose a
conflict of interest regarding the submitted manuscript. Im-
personation of another individual during the review process is
considered serious misconduct. At least one recommended re-
viewer must be a member of the journal’s editorial board.
Please provide, where indicated on the submission form, con-
tact information for suggested reviewers who are not editorial
board members.
To facilitate the review, copies of in-press and submitted
manuscripts that are important for judgment of the present
manuscript shouldbe includedas supplementalmaterial not
for publication.
When a manuscript is submitted to the journal, it is given a
control number (e.g., AAC00123-18) and assigned to one of
the editors. (Always refer to this control number in commu-
nications with the editor and the Journals Department.)
From there it is assigned to at least two independent experts for
peer review. A single-blind review, where authors’ identities
are known to reviewers, is applied. It is the responsibility of the
corresponding author to inform the coauthors of the manu-
script’s status throughout the submission, review, and publica-
tion processes. The reviewers operate under strict guidelines
set forth in “Guidelines for Reviewers” (http://www.journals
.asm.org/site/misc/reviewguide.xhtml) and are expected to com-
plete their reviews expeditiously.
The corresponding author is notified, generally within 4 to 6
weeks after submission, of the editor’s decision to accept, re-
ject, or require modification. When modification is requested,
the corresponding author must either submit the modified
version within 2 months or withdraw the manuscript. A point-
by-point response to the reviews must be uploaded as a sepa-
rate file (identified as such), and a compare copy of the man-
uscript (without figures) should be included as a Marked Up
Manuscript.
Manuscripts that have been rejected with the option to re-
submit, or withdrawn after being returned for modification,
may be resubmitted to the same ASM journal if the major
criticisms have been addressed. A manuscript rejected on sci-
entific grounds or on the basis of its general suitability for
publication by one ASM journal, with the exception of mBio®,
is considered rejected by all other ASM journals. A rejection
from mBio does not disqualify a manuscript from being newly
submitted to another ASM journal (the rejection by mBio need
not be mentioned in the cover letter). A manuscript rejected
solely on the basis of scope may be resubmitted to a more
appropriate ASM journal.
The cover letter for every resubmitted manuscript must
state that the manuscript is a resubmission, and the former
manuscript control number must be provided. A point-by-
point response to the review(s) must be uploaded as a separate
file (identified as such), and a copy of the revised manuscript
tracking the changes must be included as a Marked Up Man-
uscript. Manuscripts resubmitted to the same journal are nor-
mally handled by the original editor. Manuscripts rejected with
the option to resubmit may be resubmitted only once unless
permission has been obtained from the original editor or from
the editor in chief.
Notiﬁcation of Acceptance
When an editor has decided that a manuscript is acceptable
for publication on the basis of scientific merit, the author and
the Journals Department are notified. A PDF version of the
accepted manuscript is posted online as soon as possible (see
“AAC Accepts”).
The text files undergo an automated preediting, cleanup,
and tagging process specific to the particular article type, and
the illustrations are examined. If all files have been prepared
according to the criteria set forth in these Instructions and
those in the eJP online manuscript submission system, the ac-
ceptance procedure will be completed successfully. If there are
problems that would cause extensive corrections to be made at
the copyediting stage or if the files are not acceptable for pro-
duction, ASM Journals staff will contact the corresponding
author. Once all the material intended for publication has been
determined to be adequate, the manuscript is scheduled for the
next available issue. The editorial staff of the ASM Journals
Department completes the editing of the manuscript to bring it
into conformity with prescribed standards.
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AAC Accepts
For its primary-research journals, ASM posts online PDF
versions of manuscripts that have been peer reviewed and ac-
cepted but not yet copyedited. This feature is called “[journal
acronym] Accepts” (e.g., AAC Accepts). The manuscripts are
published online as soon as possible after acceptance, on a
weekly basis, before the copyedited, typeset articles are pub-
lished. They are posted “as is” (i.e., as submitted by the authors
at the modification stage) and do not reflect ASM editorial
changes. No corrections/changes to the PDF manuscripts are
accepted. Accordingly, there likely will be differences between
the AAC Accepts manuscripts and the final, typeset articles.
The manuscripts remain listed on the AAC Accepts page
until the final, typeset articles are posted. At that point, the
manuscripts are removed from the AAC Accepts page. The
manuscripts are under subscription access control until 6
months after the typeset articles are posted, when free access is
provided to everyone (subject to the applicable ASM license
terms and conditions). Supplemental material intended, and
accepted, for publication is not posted until publication of the
final, typeset article.
The ASM embargo policy allows a press release to be issued
as soon as the accepted manuscript is posted on the AAC Ac-
cepts page. To be notified as soon as your manuscript is posted,
please sign up for e-Alerts at http://aac.asm.org/cgi/alerts.
Instructions on how to cite such manuscripts may be found
in “References.”
Page Proofs
Page proofs, together with a query sheet and instructions for
handling proofs, will be made available to the corresponding
author electronically. Queries must be answered on the query
page, and any changes related to the queries, as well as any
additional changes, must be indicated on the proofs. Note that
the copy editor does not query at every instance where a change
has been made. Queries are written only to request necessary
information or clarification of an unclear passage or to draw at-
tention to edits that may have altered the sense. It is the author’s
responsibility to read the entire text, tables, and figure legends, not
just items queried. Corrected proofs must be returned within two
business days after notification of availability.
The proof stage is not the time to make extensive correc-
tions, additions, or deletions. Figures as they appear in the
proofs are for validation of content and placement, not quality
of reproduction or color accuracy. Print output of figures in
the PDF page proofs will be of lower quality than the same
figures viewed on a monitor. Please avoid making changes to
figures based on quality of color or reproduction in proof.
Important new information that has become available be-
tween acceptance of the manuscript and receipt of the proofs
may be inserted as an addendum in proof with the permission
of the editor. If references to unpublished data or personal
communications are added, it is expected that written assur-
ance granting permission for the citation will be included.
Limit changes to corrections of spelling errors, incorrect data,
and grammatical errors and updated information for refer-
ences to articles that have been submitted or are in press. If
URLs have been provided in the article, recheck the sites to
ensure that the addresses are still accurate and the material that
you expect the reader to find is indeed there.
Questions about proofs should be directed to the ASM Jour-
nals Department (e-mail, nlin@asmusa.org; telephone, 202-
942-9231).
PDF Files
The corresponding author will have limited access (10
downloads, total) to the PDF file of his/her published article.
An e-mail alert will automatically be sent to him/her on the day
the issue is posted. It will provide a URL, which will be required
to obtain access, and instructions. An article may be viewed,
printed, or stored, provided that it is for the author’s own use.
Should coauthors or colleagues be interested in viewing the
paper for their own use, the corresponding author may provide
them with the URL; a copy of the article may not be forwarded
electronically. However, they must be made aware of the terms
and conditions of the ASM copyright. (For details, go to http:
//www.journals.asm.org/site/misc/terms.xhtml.) Note that
each such download will count toward the corresponding au-
thor’s total of 10. After 10 downloads, access will be denied and
can be obtained only through a subscription to the journal
(either individual or institutional) or after the standard access
control has been lifted (i.e., 6 months after publication).
Funding Agency Repositories
The National Institutes of Health (NIH) requests that its
grantee and intramural authors provide copies of their ac-
cepted manuscripts to PubMed Central (PMC) for posting in
the PMC Public Access Repository. AAC authors are automat-
ically in compliance with this policy and need take no action
themselves. For the past several years, ASM has deposited in
PubMed Central all publications from all ASM journals. Fur-
ther, ASM policy is that all primary-research articles are made
available to everyone, free, 6 months after publication through
PubMed Central, HighWire, and international PubMed
Central-like repositories. By having initiated these policies,
ASM is in full compliance with NIH policy. For more informa-
tion, see https://publicaccess.nih.gov/.
ASM also allows AAC authors whose work was supported by
funding agencies that have public access requirements like
those of the NIH (e.g., the Wellcome Trust) to post their ac-
cepted manuscripts in publicly accessible electronic reposito-
ries maintained by those funding agencies. If a funding agency
does not itself maintain such a site, then ASM allows the author
to fulfill that requirement by depositing the manuscript (not
the typeset article) in an appropriate institutional or subject-
based open repository established by a government or non-
commercial entity.
Since ASM makes the final, typeset articles from its primary-
research journals available free of charge on the ASM Journals
and PMC websites 6 months after final publication, ASM re-
quests that when submitting the accepted manuscript to PMC
or a similar public access site, the author specify that the post-
ing release date for the manuscript be no earlier than 6
months after publication of the typeset article by ASM and
that a link to the published manuscript on the journal web-
site be provided.
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Publication Fees
APCs. Authors who choose open access will be assessed an
article processing charge (APC). For a corresponding author
who is an activemember of ASM at any level except the Sup-
porting member level, the APC is $2,300 (subject to change
without notice). For a nonmember or Supporting member
corresponding author, the APC is $3,150 (subject to change
without notice). Nonmember corresponding authors may join
ASM to obtain discounts on APCs. Former members who wish
to renew their membership at the same level may do so on-
line. However, to change your membership level, please
contact customer service at Service@asmusa.org. These fees
are in addition to any supplemental material charges and
permit immediate public access to both the preliminary “Accepts”
version and the copyedited, typeset version published in the on-
line journal under the Creative Commons Attribution 4.0 Inter-
national license (CC BY 4.0). This option includes immediate
open access provided through NIH’s PubMed Central repository.
When funds from the Wellcome Trust, Research Coun-
cils UK, or the Bill and Melinda Gates Foundation are used to
pay an APC, the article will be published under the CC BY 4.0
in accordance with the funding organization’s open access pol-
icies. Authors will be required to notify ASM and complete the
Author Warranty and Provisional License to Publish/CC BY
4.0 at the time of submission.
Page charges. Authors who do not choose open access and
whose research was supported by grants, special funds (including
departmental and institutional), or contracts (including govern-
mental) or whose research was done as part of their official duties
(government or corporate, etc.) are required to pay page charges
(based on the number of typeset pages, including illustrations, in
the article) and to sign the ASM copyright transfer agreement.
Corresponding authors of articles accepted for publication will
receive an e-mail notifying them how to pay page and any other
applicable publication charges (see below).
For a corresponding author who is an active member of
ASM at any level except the Supporting member level, page
charges are $80 per page (subject to change without notice).
For a nonmember or Supporting member corresponding
author, page charges are $160 per page (subject to change
without notice). Nonmember corresponding authors may join
ASM to obtain discounts on publication fees. Former members
who wish to renew their membership at the same level may do
so online. However, to change your membership level, please
contact customer service at Service@asmusa.org.
If the research was not supported by any of the means described
above, a request to waive the charges may be sent to the ASM
Journals Department (e-mail, nlin@asmusa.org [after accep-
tance of the manuscript]). The request must include the manu-
script control number assigned by ASM and indicate how the work
was supported. Waivers apply only to page charges; responsi-
bility for supplemental material fees remains with the author.
Minireviews, Commentaries, and Comment Letters to the
Editor are not subject to page charges. New-Data Letters to the
Editor are subject to page charges.
Color charges. There are no fees for color figures.
Author reprints and eprints. Reprints (in multiples of
100) and eprints (downloadable PDFs) may be purchased by
all coauthors. In addition to receiving the 10 free published
PDF files mentioned above, the corresponding authors of
Minireviews may receive 100 free eprints of their contribution
and the corresponding authors of Commentaries may receive
50 free eprints. Instructions for ordering gratis or additional
reprints and eprints can be found in the billing notification
e-mail sent to all corresponding authors. To order reprints
postpublication, please follow the instructions on the Author
Reprint Order Form. Please contact cjsreprints@cadmus.com
with any questions.
Supplemental material fee. Authors are charged a flat fee
for posting supplemental material as an adjunct to their pub-
lished article. (Exception: no fee is charged for supplemental
material associated with Minireviews or Commentaries.)
For a corresponding author who is an active member of
ASM at any level except the Supportingmember level, the sup-
plemental material fee is $210 (subject to change without notice).
For a nonmember or Supporting member corresponding au-
thor, the supplemental material fee is $320 (subject to change
without notice). Nonmember corresponding authors may join
ASM to obtain discounts on publication fees. Former members
who wish to renew their membership at the same level may do so
online. However, to change your membership level, please con-
tact customer service at Service@asmusa.org.
ORGANIZATION AND FORMAT
Editorial Style
The editorial style of ASM journals conforms to the ASM
Style Manual for Journals (American Society for Microbiology,
2018, in-house document [you may find the ASM Word List
helpful]) and HowToWrite and Publish a Scientific Paper, 7th ed.
(Greenwood, Santa Barbara, CA, 2011), as interpreted and mod-
ified by the editors and the ASM Journals Department.
The editors and the Journals Department reserve the privi-
lege of editing manuscripts to conform with the stylistic con-
ventions set forth in the aforesaid publications and in these
Instructions. Please note that ASM uses the serial comma.
On receipt at ASM, an accepted manuscript undergoes an
automated preediting, cleanup, and tagging process specific to
the particular article type. To optimize this process, manu-
scripts must be supplied in the correct format and with the
appropriate sections and headings.
Type every portion of the manuscript double-spaced (a
minimum of 6 mm between lines), including figure legends,
table footnotes, and references, and number all pages in se-
quence, including the abstract, figure legends, and tables. Place
the last two items after the References section. Manuscript
pages must have continuous line numbers; manuscripts with-
out line numbers may be editorially rejected by the editor, with
a suggestion of resubmission after line numbers are added. The
font size should be no smaller than 12 points. It is recom-
mended that the following sets of characters be easily distin-
guishable in the manuscript: the numeral zero (0) and the let-
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ter “oh” (O); the numeral one (1), the letter “el” (l), and the
letter “eye” (I); and a multiplication sign () and the letter
“ex” (x). Do not create symbols as graphics or use special
fonts that are external to your word processing program; use
the “insert symbol” function. Set the page size to 8.5 by 11
inches (ca. 21.6 by 28 cm). Italicize any words that should
appear in italics, and indicate paragraph lead-ins in boldface
type.
Manuscripts may be editorially rejected, without review,
on thebasis of poorEnglish or lackof conformity to the stan-
dards set forth in these Instructions.
Authors who are unsure of proper English usage should
have their manuscripts checked by someone proficient in the
English language or engage a professional language editing ser-
vice for help.
Manuscript Submission Checklist
• Double-space all text, including references and figure
legends.
• Number pages.
• Number lines continuously.
• Present statistical treatment of data where appropriate.
• Provide accession numbers for all newly published se-
quences in a dedicated paragraph, and if a sequence or
sequence alignment important for evaluation of the
manuscript is not yet available, provide the informa-
tion as supplemental material not for publication or
make the material available on a website for access by
the editor and reviewers.
• Format references in ASM style.
• Provide references for accession numbers and code
(with URLs).
• Confirm that genetic and chemical nomenclature con-
forms to instructions.
• Include as supplemental material not for publication
in-press and submitted manuscripts that are important
for judgment of the present manuscript.
Supplemental Material
Supplemental material will be peer reviewed along with the
manuscript and must be uploaded to the eJournalPress (eJP)
peer review system at initial manuscript submission. The deci-
sion to publish the material online with the accepted article is
made by the editor. It is possible that a manuscript will be
accepted but that the supplemental material will not be.
All supplemental text, tables, and figures should be com-
bined in a single self-contained document (PDF), and no sup-
plemental material should be included in the main manu-
script. Supplemental data set and movie files may be uploaded
separately. The number of supplemental material files is lim-
ited to 10. Supplemental files should be submitted in the fol-
lowing standard formats.
• Text, figures, tables, and legends should be included
in a single PDF file. All figures and tables should be
numbered independently and cited at the relevant
point in the manuscript text, e.g., “Fig. S1,” “Fig. S2,”
“Table S3,” etc. Do not duplicate data by presenting
them in both the text of the manuscript and a supple-
mental figure. Each legend should appear below its cor-
responding figure or table. The maximum file size is 8
MB. Please review this sample file for guidance.
• Data set (Excel [.xls]) files should include a brief de-
scription of how the data are used in the paper. The
maximum file size is 20 MB. Please review this sample
file for guidance.
• Movies (Audio Video Interleave [.avi], QuickTime
[.mov], or MPEG files) should be submitted at the de-
sired reproduction size and length and should be ac-
companied by a legend. The maximum file size is 20 MB.
Unlike the manuscript, supplemental material will not
be edited by the ASM Journals staff and proofs will not be
made available. References related to supplementalmaterial
only should not be listed in the References section of an
article; instead, include them with the supplemental mate-
rial. Supplemental material will always remain associated
with its article and is not subject to any modifications after
publication.
Material that has been published previously (print or on-
line) is not acceptable for posting as supplemental material.
Instead, the appropriate reference(s) to the original publica-
tion should be made in the manuscript.
Copyright for the supplemental material remains with the
author, but a license permitting posting by ASM is included in
the copyright transfer agreement completed by the corre-
sponding author. If you are not the copyright owner, you must
provide to ASM signed permission from the owner that allows
posting of the material, as a supplement to your article, by
ASM. You are responsible for including in the supplemental
material any copyright notices required by the owner.
See also “Publication Fees.”
Research Articles
Research Articles should include the elements described in
this section.
Title, running title, byline, affiliation line(s), and corre-
sponding author. Each manuscript should present the results
of an independent, cohesive study; thus, numbered series titles
are not permitted. Exercise care in composing a title. Avoid the
main title/subtitle arrangement, complete sentences, and un-
necessary articles. On the title page, include the title, the run-
ning title (not to exceed 54 characters and spaces), the name of
each author, all authors’ affiliations at the time the work was
performed, the name(s) and e-mail address(es) of the corre-
sponding author(s), and a footnote indicating the present ad-
dress of any author no longer at the institution where the work
was performed. Place a number sign (#) in the byline after the
affiliation letter(s) of the author to whom inquiries regarding
the paper should be directed (see “Correspondent footnote,”
below). Indicate each author’s affiliation with a superscript
lowercase letter placed after the author’s surname in the byline
(separate multiple affiliation letters with commas but no
space). Each affiliation should have its own line and its own
superscript affiliation letter preceding it. Do not consolidate
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different departments at one institution into one address with
a single affiliation letter, even if all affected authors belong to all
of those departments. Please review this sample title page for
guidance.
Study group in byline. A study group, surveillance team,
working group, consortium, or the like (e.g., the Active Bacte-
rial Core Surveillance Team) may be listed as a coauthor in the
byline if its contributing members satisfy the requirements for
authorship and accountability as described in these Instruc-
tions. The names (and institutional affiliations if desired) of
the contributing members may be given as a separate para-
graph in Acknowledgments.
If the contributing members of the group associated with the
work do not fulfill the criteria of substantial contribution to
and responsibility for the paper, the group may not be listed in
the author byline. Instead, it and the names of its contributing
members may be listed in the Acknowledgments section.
Correspondent footnote. The e-mail address for the cor-
responding author should be included on the title page of the
manuscript. This information will be published in the article as
a footnote to facilitate communication and will be used to no-
tify the corresponding author of the availability of proofs and,
later, of the PDF file of the published article. No more than two
authors may be designated corresponding authors.
Abstract. Limit the abstract to 250 words or fewer and con-
cisely summarize the basic content of the paper without pre-
senting extensive experimental details. Avoid abbreviations
and references, and do not include diagrams. When it is essen-
tial to include a reference, use the format shown under “Refer-
ences” below (see the “Citations in abstracts” section). Con-
clude the abstract with a summary statement. Because the
abstract will be published separately by abstracting services, it
must be complete and understandable without reference to the
text.
Introduction. The introduction should supply sufficient
background information to allow the reader to understand and
evaluate the results of the present study without referring to
previous publications on the topic. The introduction should
also provide the hypothesis that was addressed or the rationale
for the study. References should be chosen carefully to provide
the most salient background rather than an exhaustive review
of the topic.
Results. In the Results section, include the rationale or de-
sign of the experiments as well as the results; reserve extensive
interpretation of the results for the Discussion section. Present
the results as concisely as possible in one of the following: text,
table(s), or figure(s). Avoid extensive use of graphs to present
data that might be more concisely or more quantitatively pre-
sented in the text or tables. Limit photographs (particularly
photomicrographs and electron micrographs) to those that are
absolutely necessary to show the experimental findings. Num-
ber figures and tables in the order in which they are cited in the
text, and be sure that all figures and tables are cited.
Discussion. The Discussion should provide an interpreta-
tion of the results in relation to previously published work and
to the experimental system at hand and should not contain
extensive repetition of the Results section or reiteration of the
introduction. In short papers, the Results and Discussion sec-
tions may be combined.
Materials and Methods. The Materials and Methods sec-
tion should include sufficient technical information to allow
the experiments to be repeated. When centrifugation condi-
tions are critical, give enough information to enable another
investigator to repeat the procedure: make of centrifuge,
model of rotor, temperature, time at maximum speed, and
centrifugal force ( g rather than revolutions per minute). For
commonly used materials and methods (e.g., media and pro-
tein concentration determinations), a simple reference is suf-
ficient. If several alternative methods are commonly used, it is
helpful to identify the method briefly as well as to cite the
reference. For example, it is preferable to state “cells were bro-
ken by ultrasonic treatment as previously described (9)” rather
than “cells were broken as previously described (9).” This al-
lows the reader to assess the method without constant refer-
ence to previous publications. Describe new methods com-
pletely, and give sources of unusual chemicals, equipment, or
microbial strains. When large numbers of microbial strains or
mutants are used in a study, include tables identifying the im-
mediate sources (i.e., sources from whom the strains were ob-
tained) and properties of the strains, mutants, bacteriophages,
and plasmids, etc.
A method or strain, etc., used in only one of several experi-
ments reported in the paper may be described in the Results
section or very briefly (one or two sentences) in a table foot-
note or figure legend. It is expected that the sources from
whom the strains were obtained will be identified.
As noted above, a paragraph dedicated to new accession
numbers for nucleotide and amino acid sequences, microarray
data, protein structures, gene expression data, and MycoBank
data should appear at the end of Materials and Methods with
the paragraph lead-in “Accession number(s).” Please also pro-
vide references (with URLs) for the accession numbers.
Acknowledgments. Statements regarding sources of direct
financial support (e.g., grants, fellowships, and scholarships,
etc.) should appear in the Acknowledgments. A funding state-
ment indicating what role, if any, the funding agency had in
your study (for example, “The funders had no role in study
design, data collection and interpretation, or the decision to
submit the work for publication.”) may be included. Funding
agencies may have specific wording requirements, and compli-
ance with such requirements is the responsibility of the author.
In cases in which research is not funded by any specific project
grant, funders need not be listed, and the following statement
may be used: “This research received no specific grant from any
funding agency in the public, commercial, or not-for-profit
sectors.” Statements regarding indirect financial support (e.g.,
commercial affiliations, consultancies, stock or equity inter-
ests, and patent-licensing arrangements) are also allowed. It is
the responsibility of authors to provide a general statement
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disclosing financial or other relationships that are relevant to
the study. (See the “Conflict of Interest” section above.)
Recognition of personal assistance should be given in the
Acknowledgments section, as should any statements disclaim-
ing endorsement or approval of the views reflected in the paper
or of a product mentioned therein.
In addition to acknowledging sources of financial support in
the manuscript, authors should list any sources of funding in
response to the Funding Sources question on the online sub-
mission form, providing relevant grant numbers where possi-
ble, and the authors associated with the specific funding
sources. In the event that your submission is accepted, the
funding source information provided in the submission form
may be published, so please ensure that all information is en-
tered accurately and completely. (It will be assumed that the
absence of any information in the Funding Sources fields is a
statement by the authors that no support was received.)
Appendixes. Appendixes that contain additional material
to aid the reader are permitted. Titles, authors, and reference
sections that are distinct from those of the primary article are
not allowed. If it is not feasible to list the author(s) of
the appendix in the byline or the Acknowledgments section of
the primary article, rewrite the appendix so that it can be con-
sidered for publication as an independent article, either full-
length or Short-Form style. Equations, tables, and figures
should be labeled with the letter “A” preceding the numeral to
distinguish them from those cited in the main body of the text.
References. In the reference list, references are numbered
in the order in which they are cited in the article (citation-
sequence reference system). In the text, references are cited
parenthetically by number in sequential order. Data that are
not published or not peer reviewed are simply cited parenthet-
ically in the text (see section ii below).
(i) References listed in the References section. The follow-
ing types of references must be listed in the References section:
• Journal articles (both print and online)
• Books (both print and online)
• Book chapters (publication title is required)
• Patents
• Theses and dissertations
• Published conference proceedings
• Meeting abstracts (from published abstract books or
journal supplements)
• Letters (to the editor)
• Company publications
• In-press journal articles, books, and book chapters
• Data sets
• Code
Provide the names of all the authors and/or editors for each
reference; long bylines should not be abbreviated with
“et al.” All listed references must be cited in the text. Abbreviate
journal names according to the PubMed Journals Database (Na-
tional Library of Medicine, National Institutes of Health; available
at https://www.ncbi.nlm.nih.gov/nlmcatalog/journals), the pri-
mary source for ASM style (do not use periods with abbreviated
words). The EndNote output style for ASM Journals’ current ref-
erence style can be found at http://journals.asm.org/site/misc
/ASM_Journals.ens; click “Open” and then “Download and In-
stall” to save it to your EndNote Styles folder (it should replace any
earlier output styles for ASM journals [all ASM journals use the
same reference style]). Note that DOIs are not needed for most
references. ASM copy editors will automatically insert DOIs on all
references in the CrossRef and PubMed databases during copy-
editing. URLs for government reports and other references not
indexed in these databases should be provided if desired; URLs for
citations of database accession numbers and code/software
should be provided by you.
Follow the styles shown in the examples below.
1. Caserta E, Haemig HAH, Manias DA, Tomsic J, Grundy
FJ, Henkin TM, Dunny GM. 2012. In vivo and in vitro
analyses of regulation of the pheromone-responsive prgQ
promoter by the PrgX pheromone receptor protein. J Bac-
teriol 194:3386 –3394.
2. Bina XR, Taylor DL, Vikram A, Ante VM, Bina JE. 2013.
Vibrio choleraeToxR downregulates virulence factor produc-
tion in response to cyclo(Phe-Pro). mBio 4:e00366-13.
3. Winnick S, Lucas DO, Hartman AL, Toll D. 2005. How do
you improve compliance? Pediatrics 115:e718 – e724.
4. Falagas ME, Kasiakou SK. 2006. Use of international units
when dosing colistin will help decrease confusion related
to various formulations of the drug around the world. An-
timicrob Agents Chemother 50:2274 –2275. (Letter.)
{“Letter” or “Letter to the editor” is allowed but not required
at the end of such an entry.}
5. Cox CS, Brown BR, Smith JC. J Gen Genet, in press.* {Ar-
ticle title is optional; journal title is mandatory.}
6. Forman MS, Valsamakis A. 2011. Specimen collection,
transport, and processing: virology, p 1276 –1288. In Ver-
salovic J, Carroll KC, Jorgensen JH, Funke G, Landry ML,
Warnock DW (ed), Manual of clinical microbiology, 10th
ed, vol 2. ASM Press, Washington, DC.
7. da Costa MS, Nobre MF, Rainey FA. 2001. Genus I.
Thermus Brock and Freeze 1969, 295,AL emend. Nobre,
Tru¨per and da Costa 1996b, 605, p 404 – 414. In Boone
DR, Castenholz RW, Garrity GM (ed), Bergey’s manual
of systematic bacteriology, 2nd ed, vol 1. Springer, New
York, NY.
8. Fitzgerald G, Shaw D. In Waters AE (ed), Clinical micro-
biology, in press. EFH Publishing Co, Boston, MA.*
{Chapter title is optional.}
9. Green PN, Hood D, Dow CS. 1984. Taxonomic status of
some methylotrophic bacteria, p 251–254. In Crawford
RL, Hanson RS (ed), Microbial growth on C1 compounds.
Proceedings of the 4th International Symposium. Ameri-
can Society for Microbiology, Washington, DC.
10. Rotimi VO, Salako NO, Mohaddas EM, Philip LP. 2005.
Abstr 45th Intersci Conf Antimicrob Agents Chemother,
abstr D-1658. {Abstract title is optional.}
11. Smith D, Johnson C, Maier M, Maurer JJ. 2005. Distribu-
tion of fimbrial, phage and plasmid associated virulence
genes among poultry Salmonella enterica serovars, abstr
P-038, p 445. Abstr 105th Gen Meet Am Soc Microbiol.
American Society for Microbiology, Washington, DC.
{Abstract title is optional.}
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12. Garcı´a CO, Paira S, Burgos R, Molina J, Molina JF, Calvo
C, Vega L, Jara LJ, Garcı´a-Kutzbach A, Cuellar ML,
Espinoza LR. 1996. Detection of Salmonella DNA in syno-
vial membrane and synovial fluid from Latin American
patients using the polymerase chain reaction. Arthritis
Rheum 39(Suppl 9):S185. {Meeting abstract published in
journal supplement.}
13. O’Malley DR. 1998. PhD thesis. University of California,
Los Angeles, CA. {Title is optional.}
14. Stratagene. 2006. Yeast DNA isolation system: instruc-
tion manual. Stratagene, La Jolla, CA. {Use the company
name as the author if none is provided for a company
publication.}
15. Odell JC. April 1970. Process for batch culturing. US pat-
ent 484,363,770. {Include the name of the patented item/
process if possible; the patent number is mandatory.}
16. Harrison F, Roberts AEL, Gabrilska R, Rumbaugh KP, Lee
C, Diggle SP. 2015. A 1,000-year-old antimicrobial remedy
with antistaphylococcal activity. mBio 6:e01129-15. {Orig-
inal article that describes how data submitted to a database
were generated.}
17. Harrison F, Roberts AEL, Gabrilska R, Rumbaugh KP, Lee
C, Diggle SP. 2015. Data from “A 1,000-year-old antimi-
crobial remedy with antistaphylococcal activity.” Dryad
Digital Repository https://doi.org/10.5061/dryad.mn17p.
{Citation for the database where the data in the previous
reference were deposited; the URL is necessary.}
18. Wang Y, Rozen D. 2016. Colonization and transmission of
the gut microbiota of the burying beetle, Nicrophorus
vespilloides, through development. bioRxiv https://doi.org
/10.1101/091702.
*A reference to an in-press ASM publication should state the
control number (e.g., AAC00123-18) if it is a journal article or
the name of the publication if it is a book.
In some online journal articles, posting or revision dates
may serve as the year of publication; a DOI (preferred) or URL
is required for articles with nontraditional page numbers or
electronic article identifiers.
Magalon A, Mendel RR. 15 June 2015, posting date. Bio-
synthesis and insertion of the molybdenum cofactor. Eco-
Sal Plus 2015 doi:10.1128/ecosalplus.ESP-0006-2013.
Note: a posting or accession date is required for any online
reference that is periodically updated or changed.
Citations of ASM Accepts manuscripts should look like the
following example.
Wang GG, Pasillas MP, Kamps MP. 15 May 2006. Persis-
tent transactivation by Meis1 replaces Hox function
in myeloid leukemogenesis models: evidence for co-
occupancy of Meis1-Pbx and Hox-Pbx complexes on
promoters of leukemia-associated genes. Mol Cell Biol
doi:10.1128/MCB.00586-06.
Other journals may use different styles for their publish-
ahead-of-print manuscripts, but citation entries must include
the following information: author name(s), posting date, title,
journal title, and volume and page numbers and/or DOI. The
following is an example:
Zhou FX, Merianos HJ, Brunger AT, Engelman DM.
13 February 2001. Polar residues drive association of
polyleucine transmembrane helices. Proc Natl Acad Sci
U S A doi:10.1073/pnas.041593698
To encourage data sharing and reuse, ASM recommends
reporting data sets and/or code both in a dedicated “Data
availability” paragraph and in References. The components
of a complete data citation include the following:
• Responsible party (senior author, collector, agency),
• Publication year,
• Complete name of a data set, including the name of the
database or repository and its URL, or the name of the
analysis software (if appropriate), including the ver-
sion and project,
• Publisher (if appropriate), and
• Persistent unique identifier(s) (e.g., URL[s] or acces-
sion number[s]).
The following templates may be helpful.
Author. Year. Description of study topic. Retrieved from
Database URL (accession no.●●●●●●). {Unpublished raw
data.}
Author. Year. Description or title of software (version).
Repository URL. Retrieved day month year. {Software or
code.}
Examples follow.
Christian SL, McDonough J, Liu C-Y, Shaikh S, Vlamakis
V, Badner JA, Chakravarti A, Gershon ES. 2002. Data
from “An evaluation of the assembly of an approximately
15-Mb region on human chromosome 13q32-q33
linked to bipolar disorder and schizophrenia.” GenBank
https://www.ncbi.nlm.nih.gov/nuccore/AF339794 (acces-
sion no. AF339794). {Accession number.}
Sun Z. 2013. Reprocessed: in-depth membrane proteomic
study of breast cancer tissues. ProteomeXchange http:
//proteomecentral.proteomexchange.org/cgi/GetDataset?
IDRPXD000665 (accession number requested). {Unas-
signed accession number.}
Hogle S. 2015. Supplemental material for Hogle et al.
2015 mBio. figshare https://doi.org/10.6084/m9.figshare
.1533034.v1. Retrieved 16 March 2017. {Code and/or soft-
ware.}
Nesbitt HK, Moore JW. 2016. Data from “Species and
population diversity in Pacific salmon fisheries underpin
indigenous food security.” Dryad Digital Repository
https://doi.org/10.5061/dryad.ng8pf. {Data set in reposi-
tory.}.
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Manuscript submissions that have appeared in preprint
archives should cite the preprint in References, and the fact
that a paper has appeared online before should be mentioned
parenthetically at the end of the introductory section: (This
article was submitted to an online preprint archive [1].) The
reference should take the form noted above in reference 18.
(ii) References cited in the text. References that should be
cited in the text include the following:
• Unpublished data
• Manuscripts submitted for publication
• Unpublished conference presentations (e.g., a report
or poster that has not appeared in published confer-
ence proceedings)
• Personal communications
• Patent applications and patents pending
• Websites
These references should be made parenthetically in the text as
follows:
. . . similar results (R. B. Layton and C. C. Weathers, un-
published data).
. . . system was used (J. L. McInerney, A. F. Holden, and
P. N. Brighton, submitted for publication).
. . . as described previously (M. G. Gordon and F. L. Ratt-
ner, presented at the Fourth Symposium on Food Mi-
crobiology, Overton, IL, 13 to 15 June 1989). {For non-
published abstracts and posters, etc.}
. . . this new process (V. R. Smoll, 20 June 1999, Austra-
lian Patent Office). {For non-U.S. patent applications,
give the date of publication of the application.}
. . . as suggested by the World Health Organization (http://
www.who.int/campaigns/immunization-week/2017/
en/).
URLs for companies that produce any of the products men-
tioned in your study or for products being sold may not be
included in the article. However, company URLs that permit
access to scientific data related to the study or to shareware
used in the study are permitted.
(iii) Citations in abstracts. Because the abstract must be
able to stand apart from the article, references cited in it
should be clear without recourse to the References section. Use
an abbreviated form of citation, omitting the article title, as
follows.
(P. S. Satheshkumar, A. S. Weisberg, and B. Moss, J Virol
87:10700 –10709, 2013, doi:10.1128/JVI.01258-13)
(J. H. Coggin, Jr., p. 93–114, in D. O. Fleming and D. L.
Hunt, ed., Biological Safety. Principles and Practices, 4th
ed., 2006)
“. . . in a recent report by D. A. Hopwood (mBio
4:e00612-13, 2013, doi:10.1128/mBio00612-13) . . . .”
This style should also be used for Addenda in Proof.
(iv) References related to supplemental material. If refer-
ences must be cited in the supplemental material, list them in a
separate References section within the supplemental material
and cite them by those numbers; do not simply include cita-
tions of numbers from the reference list of the associated
article. If the same reference(s) is to be cited in both the article
itself and the supplemental material, then that reference would
be listed in both References sections.
Short-Form Papers
The Short-Form format is intended for the presentation of
brief observations that do not warrant full-length Research
Articles. Submit Short-Form papers in the same way as Re-
search Articles. They receive the same review, they are not pub-
lished more rapidly than Research Articles, and they are not
considered preliminary communications.
The title, running title (not to exceed 54 characters and
spaces), byline, and correspondent footnote should be pre-
pared as for a Research Article. Each Short-Form paper must
have an abstract of no more than 75 words. Do not use section
headings in the body of the paper; combine methods, results,
and discussion in a single section. Paragraph lead-ins are per-
missible. The text should be kept to a minimum and if possible
should not exceed 1,000 words; the number of figures and
tables should also be kept to a minimum. Materials and methods
should be described in the text, not in figure legends or table foot-
notes. Present acknowledgments as in Research Articles. The Ref-
erences section is identical to that of Research Articles.
Minireviews
Minireviews are brief (limit of 6,000words exclusive of ref-
erences) biographical profiles, historical perspectives, or sum-
maries of developments in fast-moving areas of chemotherapy.
They must be based on published articles; they are not outlets
for unpublished data. They may address any subject within the
scope of AAC. For example, subject matter may range from
structure-activity correlates among a group of semisynthetic
cephalosporins to the comparative efficacies of new and old
drugs in the prevention or treatment of diseases
of microbial origin in humans.
Minireviews may be either solicited or proffered by authors
responding to a recognized need. Irrespective of origin, Minire-
views are subject to review and should be submitted via the eJP
online manuscript submission and peer review system. The cover
letter should state whether the article was solicited and by whom.
Minireviews must have abstracts. Limit the abstract to 250
words or fewer. The body of the Minireview may have section
headings and/or paragraph lead-ins.
Author bios. At the editor’s invitation, corresponding au-
thors of minireviews may submit a short biographical sketch
and photo for each author for publication with the article.
Biographical information should be submitted at the modifi-
cation stage.
• The text limit is 150 words for each author and should
include WHO you are (your name), WHERE you re-
ceived your education, WHAT positions you have held
and at WHICH institutions, WHERE you are now
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(your current institution), WHY you have this interest,
and HOW LONG you have been in this field.
• The photo should be a black-and-white head shot of
passport size. Photos will be reduced to approximately
1.125 inches wide by 1.375 inches high. Photos must
meet the production criteria for regular figures
and should be checked for production quality by
using Rapid Inspector, provided at the following URL:
http://rapidinspector.cadmus.com/RapidInspector
/zmw/index.jsp.
• To submit, upload the text and photos with your mod-
ified manuscript in the eJP online manuscript submis-
sion and peer review system. Include the biographical
text after the References section of your manuscript, in
the same file. Upload the head shots in the submission
system as a “Minireview Bio Photo”; include the au-
thor’s name or enough of it for identification in each
photo’s file name.
Contact the scientific editor if you have questions about what
to write. Contact the production editor if you have questions
about submitting your files.
Commentaries
Commentaries are invited communications concerning
topics relevant to the readership of AAC and are intended to
engender discussion. Reviews of the literature, methods and
other how-to papers, and responses targeted at a specific pub-
lished paper are not appropriate. Commentaries are subject to
review.
The length may not exceed 4,000 words, and the format is
like that of a Minireview (see above) except that the abstract is
limited to 75 words.
Challenging Clinical Cases in Antimicrobial Resistance
Challenging Clinical Cases are brief articles designed to fa-
miliarize and provide guidance to the reader on the clinical
approach to the treatment of real, challenging cases involving
multidrug-resistant organisms (bacteria, viruses, fungi, and
parasites). This section is focused on providing an up-to-date
scientific rationale for choosing specific antimicrobials based
on available clinical, microbiological, and pharmacological
data and on discussing the impact of mechanisms of resistance
on the outcomes for infected patients. These articles may dis-
cuss novel therapeutic strategies for treating patients infected
with multidrug-resistant organisms. Only highly interesting
cases that have important mechanistic and epidemiological or
novel microbiological insights will be selected for review.
The article should include (i) a brief abstract (limit of 75
words); (ii) a case section describing a single clinical case up to
the point when the organism is isolated, characterization of the
organism, and information about susceptibility testing, when
appropriate; (iii) interesting photos, figures, and/or tables
(limit of two combined) highlighting the clinical presentation
(see “Illustrations and Tables” below for guidelines on accept-
able file types, resolution, size, etc.); (iv) a single multiple-
choice question addressing the most relevant therapeutic is-
sues (How would you interpret the susceptibility report?
Which antimicrobials would be best for the patient presented
in the case and why? What are the underlying mechanisms of
resistance? Are there any particular pharmacological strategies,
in terms of drug administration, delivery, etc., that could help
in treating this patient?) with several possible answers as choic-
es; (v) a description of the treatment strategy and patient out-
come; and (vi) a reference list containing no more than 10
references. Sections ii and v above (case presentation and strat-
egy/outcome) must not exceed 1,200 words combined.
An expert in the field (a reviewer) will discuss the case in a
brief commentary section and explore answers to the questions
posed by the author. (The commentator’s name and role will
appear at the end of the published article byline.)
These articles will be made freely available to readers at the
time of publication. No page charges will be associated with
these articles, but the standard fee for accepted supplemental
material, if any, applies. In an attempt to stimulate conversa-
tions and engagement, readers will be able to add comments
via an online feature.
Letters to the Editor
Two types of Letters to the Editor may be submitted. The
first type (Comment Letter) is intended for comments on
final, typeset articles published in the journal (not on ac-
cepted manuscripts posted online) and must cite published
references to support the writer’s argument. The second
type (New-Data Letter) may report new, concise findings
that are not appropriate for publication as Research Articles
or Short-Form papers.
Letters may be no more than 500 words long and must be
typed double-spaced. Refer to a recently published Letter for
correct formatting. Note that authors and affiliations are listed
below the title.
All Letters to the Editor must be submitted electronically,
and the type of Letter (New Data or Comment) must be se-
lected from the choices in the submission form. For Letters
commenting on published articles, the cover letter should state
the volume and issue in which the article was published, the
title of the article, and the last name of the first author. In the
Abstract section of the submission form, put “Not Applicable.”
Letters to the Editor do not have abstracts. Both types of Letter
must have a title, which must appear on the manuscript and on
the submission form. Figures and tables should be kept to a
minimum.
If the Letter is related to a published article, it will be sent to
the editor who handled the article in question. If the editor
believes that publication is warranted, he/she will solicit a reply
from the corresponding author of the article and give approval
for publication.
New-Data Letters will be assigned to an editor according to
subject matter and will be reviewed by that editor and/or a
reviewer.
Please note that some indexing/abstracting services do not
include Letters to the Editor in their databases.
Errata
Errata provide a means of correcting errors that occurred
during the writing, typing, editing, or publication (e.g., a
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misspelling, a dropped word or line, or mislabeling in a
figure) of a published article. Submit Errata via the eJP on-
line manuscript submission and peer review system (see
“Submission, Review, and Publication Processes”). In the
Abstract section of the submission form (a required field),
put “Not Applicable.” Upload the text of your Erratum as a
Microsoft Word file. Please see a recent issue for correct
formatting.
Author Corrections
Author Corrections provide a means of correcting errors of
omission (e.g., author names or citations) and errors of a sci-
entific nature that do not alter the overall basic results or con-
clusions of a published article (e.g., an incorrect unit of
measurement or order of magnitude used throughout, con-
tamination of one of numerous cultures, or misidentification
of a mutant strain, causing erroneous data for only a [noncrit-
ical] portion of the study). Note that the addition of new data is
not permitted.
For corrections of a scientific nature or issues involving au-
thorship, including contributions and use or ownership of data
and/or materials, all disputing parties must agree, in writing, to
publication of the Correction. For omission of an author’s
name, letters must be signed by the authors of the article and
the author whose name was omitted. The editor who handled
the article will be consulted if necessary.
Submit an Author Correction via the eJP online manuscript
submission and peer review system (see “Submission, Review,
and Publication Processes”). Select Author Correction as the
manuscript type. In the Abstract section of the submission
form (a required field), put “Not Applicable.” Upload the text
of your Author Correction as a Microsoft Word file. Please see
a recent issue for correct formatting. Signed letters of agree-
ment must be supplied as supplemental material not for pub-
lication (scanned PDF files).
Retractions
Retractions are reserved for major errors or breaches of eth-
ics that, for example, may call into question the source of the
data or the validity of the results and conclusions of an article.
Submit Retractions via the eJP online manuscript submission
and peer review system (see “Submission, Review, and Publi-
cation Processes”). In the Abstract section of the submission
form (a required field), put “Not Applicable.” Upload the text
of your Retraction as a Microsoft Word file. Letters of agree-
ment signed by all of the authors must be supplied as supple-
mental material not for publication (scanned PDF files). The
Retraction will be assigned to the editor in chief of the journal,
and the editor who handled the paper and the chairperson of
the ASM Journals Board will be consulted. If all parties agree to
the publication and content of the Retraction, it will be sent to
the Journals Department for publication.
CrossMark
ASM has implemented CrossMark. CrossMark is a multi-
publisher initiative to provide a standard way for readers to
locate the current version of an article. Clicking on the Cross-
Mark logo will indicate whether an article is current or whether
updates have been published. Additional information about
CrossMark can be found on CrossMark’s website and on
ASM’s CrossMark policy page.
ILLUSTRATIONS AND TABLES
Illustrations
Image manipulation. Digital images submitted for publi-
cation may be inspected by ASM production specialists for any
manipulations or electronic enhancements that may be con-
sidered to be the result of scientific misconduct based on the
guidelines provided below. Any images/data found to contain
manipulations of concern will be referred to the editor in chief,
and authors may then be requested to provide their primary
data for comparison with the submitted image file. Investiga-
tion of the concerns may delay publication and may result in
revocation of acceptance and/or additional action by ASM.
Linear adjustments to contrast, brightness, and/or color are
generally acceptable, as long as the measures taken are neces-
sary to view elements that are already present in the data and
the adjustments are applied to the entire image and not just
specific areas. Unacceptable adjustments to images include,
but are not limited to, the removal or deletion, concealment,
duplication (copying and pasting), addition, selective en-
hancement, or repositioning of elements within the image.
Nonlinear adjustments made to images, such as changes to
gamma settings, should be fully disclosed in the figure legends
at the time of submission. In addition, images created by com-
piling multiple files, including noncontiguous portions of the
same image, should clearly convey that these multiple files are
not a single image. This can be done by “tooling,” or inserting
thin lines, between the individual images.
File types and formats. Illustrations may be continuous-
tone images, line drawings, or composites. Color graphics may
be submitted. Suggestions about how to ensure accurate color
reproduction are given below.
On initial submission, figures may be uploaded as individual
PDF files or combined and uploaded as a single PDF file. Place
each legend in the text file, as well as on the same page with the
corresponding figure to assist review. At the modification
stage, production-quality digital files must be provided. Be-
cause the legends will be copyedited and typeset for final pub-
lication, they should appear within the main text, after the
References section, and should not be included as part of the
figure itself at this stage. All graphics submitted with modified
manuscripts must be bitmap, grayscale, or in the RGB (pre-
ferred) or CMYK color mode. See “Color illustrations.” Half-
tone images (those with various densities or shades) must be
grayscale, not bitmap. AAC accepts TIFF or EPS files but dis-
courages PowerPoint for either black-and-white or color im-
ages.
For instructions on creating acceptable EPS and TIFF files, refer
to the Cadmus digital art website, http://art.cadmus.com/da
/index.jsp. PowerPoint requires users to pay close attention to the
fonts used in their images (see the section on fonts below). If
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instructions for fonts are not followed exactly, images prepared
for publication are subject to missing characters, improperly con-
verted characters, or shifting/obscuring of elements or text in
the figure. For proper font use in PowerPoint images, refer to
the Cadmus digital art website, http://art.cadmus.com/da
/instructions/ppt_disclaimer.jsp. Note that, due to page compo-
sition system requirements, you must verify that your PowerPoint
files can be converted to PDF without any errors.
We strongly recommend that before returning theirmod-
ified manuscripts, authors check the acceptability of their
digital images for production by running their files through
Rapid Inspector, a tool provided at the following URL:
http://rapidinspector.cadmus.com/RapidInspector/zmw
/index.jsp. Rapid Inspector is an easy-to-use, Web-based
application that identifies file characteristics that may ren-
der the image unusable for production. Please note when
using Rapid Inspector to check PowerPoint files that there is
a known bug in the application that can occasionally fail
PowerPoint Presentation (.pptx) files, even though the files
meet all required production criteria. If you experience this
bug, the issue can be corrected by saving the PowerPoint
files as an older version, PowerPoint 97-2004 Presentation
(.ppt), during the Save As process (use the drop-down for-
mat menu and select this format). Once you save your files
as .ppt, they will pass Rapid Inspector if all required produc-
tion criteria have been met.
If you have additional questions about using the Rapid In-
spector preflighting tool, please send an e-mail inquiry to
helpdesk.digitalartsupport@cenveo.com.
Minimum resolution. It is extremely important that a
high enough file resolution is used. All separate images that
you import into a figure file must be at the correct resolution
before they are placed. (For instance, placing a 72-dpi image
in a 300-dpi EPS file will not result in the placed image
meeting the minimum requirements for file resolution.)
Note, however, that the higher the resolution, the larger the
file and the longer the upload time. Publication quality will
not be improved by using a resolution higher than the min-
imum. Minimum resolutions are as follows:
• 300 dpi for grayscale and color
• 600 dpi for combination art (lettering and images)
• 1,200 dpi for line art
Size. All graphics should be submitted at their intended
publication size so that no reduction or enlargement is nec-
essary. Resolution must be at the required level at the sub-
mitted size. Include only the significant portion of an illus-
tration. White space must be cropped from the image, and
excess space between panel labels and the image must be
eliminated.
• Maximum figure width: 6.875 inches (ca. 17.4 cm)
• Maximum figure height: 9.0625 inches (23.0 cm)
Contrast. Illustrations must contain sufficient contrast to
be viewed easily on a monitor or on the printed page.
Labeling and assembly. All final lettering and labeling
must be incorporated into the figures. On initial submis-
sion, illustrations should be provided as PDF files, with the
legends in the text file and with a legend beneath each image
to assist review. At the modification stage, production-
quality digital figure files (without legends) must be pro-
vided. Put the figure number well outside the boundaries of
the image itself. (Numbering may need to be changed at the
copyediting stage.) Each figure must be uploaded as a sepa-
rate file, and any multipanel figures must be assembled into
one file; i.e., rather than uploading a separate file for each
panel in a figure, assemble all panels in one piece and supply
them as one file.
Fonts. To avoid font problems, set all type in one of the
following fonts: Arial, Helvetica, Times Roman, European
PI, Mathematical PI, or Symbol. Courier may be used but
should be limited to nucleotide or amino acid sequences in
which a nonproportional (monospace) font is required. All
fonts other than these must be converted to paths (or out-
lines) in the application with which they were created.
Color illustrations. All figures submitted in color will be
processed as color. Adherence to the following guidelines
will help to ensure color reproduction that is as accurate as
possible.
The final online version is considered the version of record
for AAC and all other ASM journals. To maximize online re-
production, color illustrations should be supplied in the RGB
color mode as either (i) RGB TIFF images with a resolution of
at least 300 pixels per inch (raster files, consisting of pixels) or
(ii) Illustrator-compatible EPS files with RGB color elements
(vector files, consisting of lines, fonts, fills, and images). CMYK
files are also accepted. Other than in color space, CMYK files
must meet the same production criteria as RGB files. The RGB
color space is the native color space of computer monitors and
of most of the equipment and software used to capture scien-
tific data, and it can display a wider range of colors (especially
bright fluorescent hues) than the CMYK (cyan, magenta, yel-
low, black) color space used by print devices that put ink (or
toner) on paper. For reprints, ASM’s print provider will auto-
matically create CMYK versions of color illustrations from
the supplied RGB versions. Color in the reprints may not
match that in the online journal of record because of the
smaller range of colors capable of being reproduced by CMYK
inks on a printing press. For additional information on RGB
versus CMYK color, refer to the Cadmus digital art site, http:
//art.cadmus.com/da/guidelines_rgb.jsp.
Drawings. Submit graphs, charts, complicated chemical
or mathematical formulas, diagrams, and other drawings as
finished products not requiring additional artwork or type-
setting. All elements, including letters, numbers, and sym-
bols, must be easily readable, and both axes of a graph must
be labeled.
When creating line art, please use the following guidelines:
(i) All art must be submitted at its intended publication
size. For acceptable dimensions, see “Size,” above.
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(ii) Avoid using screens (i.e., shading) in line art. It can be
difficult and time-consuming to reproduce these images with-
out moire´ patterns. Various pattern backgrounds are prefera-
ble to screens as long as the patterns are not imported from
another application. If you must use images containing
screens,
(a) Generate the image at line screens of 85 lines per inch
or less.
(b) When applying multiple shades of gray, differentiate
the gray levels by at least 20%.
(c) Never use levels of gray below 5% or above 95% as they
are likely to fade out or become totally black when output.
(iii) Use thick, solid lines that are no finer than 1 point in
thickness.
(iv) Use type that is no smaller than 6 points at the final
publication size.
(v) Avoid layering type directly over shaded or textured ar-
eas.
(vi) Avoid the use of reversed type (white lettering on a black
background).
(vii) Avoid heavy letters, which tend to close up, and un-
usual symbols, which the printer may not be able to reproduce
in the legend.
(viii) If colors are used, avoid using similar shades of the
same color and avoid very light colors.
In figure ordinate and abscissa scales (as well as table column
headings), avoid the ambiguous use of numbers with expo-
nents. Usually, it is preferable to use the Syste`me International
d’Unite´s (SI) symbols ( for 106, m for 103, k for 103, and M
for 106, etc.). Thus, a representation of 20,000 cpm on a figure
ordinate should be made by the number 20 accompanied by the
label kcpm. A complete listing of SI symbols can be found in the
International Union of Pure and Applied Chemistry (IUPAC)
publication Quantities, Units and Symbols in Physical Chemistry,
3rd ed. (RSC Publishing, Cambridge, United Kingdom, 2007),
and at https://www.nist.gov/physical-measurement-laboratory
/special-publication-811.
When powers of 10 must be used, the journal requires that
the exponent power be associated with the number shown. In
representing 20,000 cells per ml, the numeral on the ordinate
should be “2” and the label should be “104 cells per ml” (not
“cells per ml  104”). Likewise, an enzyme activity of 0.06
U/ml might be shown as 6 accompanied by the label “102
U/ml.” The preferred designation is 60 mU/ml (milliunits per
milliliter).
Presentation of Nucleic Acid Sequences
Long nucleic acid sequences must be presented as figures
in the following format to conserve space. Print the se-
quence in lines of approximately 100 to 120 nucleotides in a
nonproportional (monospace) font that is easily legible
when published with a line length of 6 inches (ca. 15.2 cm).
If possible, lines of nucleic acid sequence should be further
subdivided into blocks of 10 or 20 nucleotides by spaces
within the sequence or by marks above it. Uppercase and
lowercase letters may be used to designate the exon-intron
structure or transcribed regions, etc., if the lowercase letters
remain legible at a 6-inch (ca. 15.2-cm) line length. Number
the sequence line by line; place numerals representing the
first base of each line to the left of the lines. Minimize spac-
ing between lines of sequence, leaving room only for anno-
tation of the sequence. Annotation may include boldface,
underlining, brackets, and boxes, etc. Encoded amino acid
sequences may be presented, if necessary, immediately
above or below the first nucleotide of each codon, by using
the single-letter amino acid symbols. Comparisons of mul-
tiple nucleic acid sequences should conform as nearly as
possible to the same format.
Figure Legends
On initial submission, each legend should be placed in the
text file and be incorporated into the image file beneath the
figure to assist review.
Legends should provide enough information so that the fig-
ure is understandable without frequent reference to the text.
However, detailed experimental methods must be described in
the Materials and Methods section, not in a figure legend. A
method that is unique to one of several experiments may be set
forth in a legend only if the description is very brief (one or two
sentences). Define all symbols used in the figure and define all
abbreviations that are not used in the text.
Tables
Tables that contain artwork, chemical structures, or com-
plex shading must be submitted as illustrations in an accept-
able format at the modification stage. The preferred format for
regular tables is Microsoft Word; however, WordPerfect and
Acrobat PDF are also acceptable. Note that a straight Excel file
is not currently an acceptable format. Excel files must be either
embedded in a Word or WordPerfect document or converted
to PDF before being uploaded.
Tables should be formatted as follows. Arrange the data so
that columns of like material read down, not across. The
headings should be sufficiently clear so that the meaning of
the data is understandable without reference to the text. See the
“Abbreviations” section of these Instructions for those that
should be used in tables. Explanatory footnotes are acceptable,
but more-extensive table “legends” are not. Footnotes should
not include detailed descriptions of the experiment. Tables
must include enough information to warrant table format;
those with fewer than six pieces of data will be incorporated
into the text by the copy editor. Table 1 is an example of a
well-constructed table.
Avoid tables (or figures) of raw data on drug susceptibility,
therapeutic activity, or toxicity. Such data should be analyzed
by an approved procedure, and the results should be presented
in tabular form.
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NOMENCLATURE
Chemical and Biochemical Nomenclature
The recognized authority for the names of chemical com-
pounds is Chemical Abstracts (CAS; http://www.cas.org/) and
its indexes. The Merck Index Online (https://www.rsc.org/
merck-index) is also an excellent source. For guidelines to the
use of biochemical terminology, consult Biochemical Nomen-
clature and Related Documents (Portland Press, London,
United Kingdom, 1992), available at http://www.sbcs.qmul.ac
.uk/iupac/bibliog/white.html, and the Instructions to Authors
of the Journal of Biological Chemistry.
Molecular weight should not be expressed in daltons; mo-
lecular weight is a unitless ratio. Molecular mass is expressed in
daltons.
For enzymes, use the recommended (trivial) name as as-
signed by the Nomenclature Committee of the International
Union of Biochemistry (IUB) as described in Enzyme No-
menclature (Academic Press, Inc., New York, NY, 1992) and
its supplements and at http://www.sbcs.qmul.ac.uk/iubmb
/enzyme/. If a nonrecommended name is used, place the
proper (trivial) name in parentheses at first use in the abstract
and text. Use the EC number when one has been assigned.
Authors of papers describing enzymological studies should re-
view the standards of the STRENDA Commission for informa-
tion required for adequate description of experimental condi-
tions and for reporting enzyme activity data (http://www
.beilstein-institut.de/en/projects/strenda/guidelines).
Nomenclature of Microorganisms
Binary names, consisting of a generic name and a specific
epithet (e.g., Escherichia coli), must be used for all microorgan-
isms. Names of categories at or above the genus level may be
used alone, but specific and subspecific epithets may not. A
specific epithet must be preceded by a generic name, written
out in full the first time it is used in a paper. Thereafter, the
generic name should be abbreviated to the initial capital letter
(e.g., E. coli), provided there can be no confusion with other
genera used in the paper. Names of all bacterial taxa (king-
doms, phyla, classes, orders, families, genera, species, and sub-
species) are printed in italics and should be italicized in the
manuscript; strain designations and numbers are not. Ver-
nacular (common) names should be in lowercase roman type
(e.g., streptococcus, brucella). For Salmonella, genus, species,
and subspecies names should be rendered in standard form:
Salmonella enterica at first use, S. enterica thereafter; Salmo-
nella enterica subsp. arizonae at first use, S. enterica subsp. ari-
zonae thereafter. Names of serovars should be in roman type
with the first letter capitalized: Salmonella enterica serovar
Typhimurium. After the first use, the serovar may also be given
without a species name: Salmonella Typhimurium, S. Typhi-
murium, or Salmonella serovar Typhimurium. For other in-
formation regarding serovar designations, see Antigenic For-
mulae of the Salmonella Serovars, 9th ed. (P. A. D. Grimont
and F.-X. Weill, WHO Collaborating Centre for Reference
and Research on Salmonella, Institut Pasteur, Paris, France,
2007; see http://www.scacm.org/free/Antigenic%20Formulae
%20of%20the%20Salmonella%20Serovars%202007%209th%
20edition.pdf). For a summary of the current standards for
Salmonella nomenclature and the Kaufmann-White criteria,
see the article by Brenner et al. (J Clin Microbiol 38:2465–2467,
2000), the opinion of the Judicial Commission of the Interna-
tional Committee on Systematics of Prokaryotes (Int J Syst
Evol Microbiol 55:519 –520, 2005), and the article by Tindall et
al. (Int J Syst Evol Microbiol 55:521–524, 2005).
The spelling of bacterial names should follow the Approved
Lists of Bacterial Names (Amended) & Index of the Bacterial and
Yeast Nomenclatural Changes (V. B. D. Skerman et al., ed.,
American Society for Microbiology, Washington, DC, 1989)
and the validation lists and notification lists published in the
International Journal of Systematic and EvolutionaryMicrobiol-
ogy (formerly the International Journal of Systematic Bacteriol-
ogy) since January 1989. In addition, two sites on the World
Wide Web list current approved bacterial names: Prokaryotic
Nomenclature Up-to-Date (https://www.dsmz.de/bacterial
-diversity/prokaryotic-nomenclature-up-to-date.html) and List
of Prokaryotic Names with Standing in Nomenclature (http://www
.bacterio.net/). If there is reason to use a name that does not
have standing in nomenclature, the name should be enclosed
in quotation marks in the title and at its first use in the abstract
and the text and an appropriate statement concerning the
nomenclatural status of the name should be made in the text.
“Candidatus” species should always be set in quotation marks.
Since the classification of fungi is not complete, it is the
responsibility of the author to determine the accepted bino-
mial for a given organism. Sources for these names include
TheYeasts: aTaxonomic Study, 5th ed. (C. P. Kurtzman, J. W. Fell,
and T. Boekhout, ed., Elsevier Science, Amsterdam, Netherlands,
2011), and Dictionary of the Fungi, 10th ed. (P. M. Kirk, P. F.
Cannon, D. W. Minter, and J. A. Stalpers, ed., CABI International,
Wallingford, Oxfordshire, United Kingdom, 2008); see also http:
//www.speciesfungorum.org/Names/Fundic.asp.
Names used for viruses should be those approved by the
International Committee on Taxonomy of Viruses (ICTV)
and reported on the ICTV Virus Taxonomy website (https:
//talk.ictvonline.org/). In addition, the recommendations of
the ICTV regarding the use of species names should generally
be followed: when the entire species is discussed as a taxonomic
entity, the species name, as with other taxa, is italic and has the
first letter and any proper nouns capitalized (e.g., Tobacco mosaic
virus,MurrayValley encephalitis virus). When the behavior or ma-
nipulation of individual viruses is discussed, the vernacular (e.g.,
tobacco mosaic virus, Murray Valley encephalitis virus) should be
used. If desired, synonyms may be added parenthetically when the
TABLE 1 Distribution of protein and ATPase in fractions of dialyzed
membranesa
Membrane Fraction
ATPase
U/mg of protein Total U
Control Depleted membrane 0.036 2.3
Concentrated supernatant 0.134 4.82
E1 treated Depleted membrane 0.034 1.98
Concentrated supernatant 0.11 4.6
a Specific activities of ATPase of nondepleted membranes from control and treated
bacteria were 0.21 and 0.20, respectively.
Instructions to Authors
January 2018, Instructions to Authors aac.asm.org 19Antimicrobial Agents and Chemotherapy
name is first mentioned. Approved generic (or group) and family
names may also be used.
Microorganisms, viruses, and plasmids should be given des-
ignations consisting of letters and serial numbers. It is gener-
ally advisable to include a worker’s initials or a descriptive sym-
bol of locale or laboratory, etc., in the designation. Each new
strain, mutant, isolate, or derivative should be given a new
(serial) designation. This designation should be distinct from
those of the genotype and phenotype, and genotypic and phe-
notypic symbols should not be included. Plasmids are named
with a lowercase “p” followed by the designation in uppercase
letters and numbers. To avoid the use of the same designation
as that of a widely used strain or plasmid, check the designation
against a publication database such as Medline.
Genetic Nomenclature
To facilitate accurate communication, it is important that
standard genetic nomenclature be used whenever possible
and that deviations or proposals for new naming systems be
endorsed by an appropriate authoritative body. Review
and/or publication of submitted manuscripts that contain new
or nonstandard nomenclature may be delayed by the editor or
the Journals Department so that they may be reviewed.
Bacteria. The genetic properties of bacteria are described in
terms of phenotypes and genotypes. The phenotype describes
the observable properties of an organism. The genotype refers
to the genetic constitution of an organism, usually in reference
to some standard wild type. The guidelines that follow are
based on the recommendations of Demerec et al. (Genetics
54:61–76, 1966).
(i) Phenotype designations must be used when mutant loci
have not been identified or mapped. They can also be used to
identify the protein product of a gene, e.g., the OmpA protein.
Phenotype designations generally consist of three-letter sym-
bols; these are not italicized, and the first letter of the symbol is
capitalized. It is preferable to use Roman or Arabic numerals
(instead of letters) to identify a series of related phenotypes.
Thus, a series of nucleic acid polymerase mutants might be
designated Pol1, Pol2, and Pol3, etc. Wild-type characteristics
can be designated with a superscript plus (Pol), and, when
necessary for clarity, negative superscripts (Pol) can be used
to designate mutant characteristics. Lowercase superscript let-
ters may be used to further delineate phenotypes (e.g., Strr for
streptomycin resistance). Phenotype designations should be
defined.
(ii) Genotype designations are also indicated by three-letter
locus symbols. In contrast to phenotype designations, these are
lowercase italic (e.g., ara his rps). If several loci govern related
functions, these are distinguished by italicized capital letters
following the locus symbol (e.g., araA araB araC). Promoter,
terminator, and operator sites should be indicated as described
by Bachmann and Low (Microbiol Rev 44:1–56, 1980): e.g.,
lacZp, lacAt, and lacZo.
(iii) Wild-type alleles are indicated with a superscript plus
(ara his). A superscript minus is not used to indicate a mu-
tant locus; thus, one refers to an ara mutant rather than an
ara strain.
(iv) Mutation sites are designated by placing serial isolation
numbers (allele numbers) after the locus symbol (e.g., araA1
araA2). If only a single such locus exists or if it is not known in
which of several related loci the mutation has occurred, a hy-
phen is used instead of the capital letter (e.g., ara-23). It is
essential in papers reporting the isolation of new mutants that
allele numbers be given to the mutations. For Escherichia coli,
there is a registry of such numbers: E. coli Genetic Stock Center
(http://cgsc2.biology.yale.edu/). For the genus Salmonella, the
registry is Salmonella Genetic Stock Center (http://people
.ucalgary.ca/~kesander/). For the genus Bacillus, the registry is
Bacillus Genetic Stock Center (http://www.bgsc.org/).
(v) The use of superscripts with genotypes (other than to
indicate wild-type alleles) should be avoided. Designations in-
dicating amber mutations (Am), temperature-sensitive muta-
tions (Ts), constitutive mutations (Con), cold-sensitive muta-
tions (Cs), production of a hybrid protein (Hyb), and other
important phenotypic properties should follow the allele num-
ber [e.g., araA230(Am) hisD21(Ts)]. All other such designa-
tions of phenotype must be defined at the first occurrence. If
superscripts must be used, they must be approved by the editor
and defined at the first occurrence in the text.
Subscripts may be used in two situations. Subscripts may be
used to distinguish between genes (having the same name)
from different organisms or strains; e.g., hisE. coli or hisK-12 for
the his gene of E. coli or strain K-12, respectively, may be used
to distinguish this gene from the his gene in another species or
strain. An abbreviation may also be used if it is explained. Sim-
ilarly, a subscript is also used to distinguish between genetic
elements that have the same name. For example, the promoters
of the gln operon can be designated glnAp1 and glnAp2. This
form departs slightly from that recommended by Bachmann
and Low (e.g., desC1p).
(vi) Deletions are indicated by the symbol  placed before
the deleted gene or region, e.g.,trpA432,(aroP-aceE)419, or
(hisQ-hisJo)1256. Similarly, other symbols can be used (with
appropriate definition). Thus, a fusion of the ara and lac oper-
ons can be shown as (ara-lac)95. Likewise, (araB-
lacZ)96 indicates that the fusion results in a truncated araB
gene fused to an intact lacZ gene, and (malE-lacZ)97(Hyb)
shows that a hybrid protein is synthesized. An inversion is
shown as IN(rrnD-rrnE)1. An insertion of an E. coli his gene
into plasmid pSC101 at zero kilobases (0 kb) is shown as
pSC101 	(0kb::K-12hisB)4. An alternative designation of an
insertion can be used in simple cases, e.g., galT236::Tn5. The
number 236 refers to the locus of the insertion, and if the strain
carries an additional gal mutation, it is listed separately. Addi-
tional examples, which utilize a slightly different format, can be
found in the papers by Campbell et al. and Novick et al. cited
below. It is important in reporting the construction of strains
in which a mobile element was inserted and subsequently de-
leted that this fact be noted in the strain table. This can be done
by listing the genotype of the strain used as an intermediate in
a table footnote or by making a direct or parenthetical remark
in the genotype, e.g., (F), Mu cts, or mal::Mu cts::lac. In
setting parenthetical remarks within the genotype or dividing
the genotype into constituent elements, parentheses and brackets
are used without special meaning; brackets are used outside pa-
rentheses. To indicate the presence of an episome, parentheses (or
brackets) are used (, F). Reference to an integrated episome is
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indicated as described above for inserted elements, and an exog-
enote is shown as, for example, W3110/F8(gal).
For information about genetic maps of locus symbols in
current use, consult Berlyn (Microbiol Mol Biol Rev 62:814 –
984, 1998) forE. coliK-12, Sanderson and Roth (Microbiol Rev
52:485–532, 1988) for Salmonella serovar Typhimurium, Hol-
loway et al. (Microbiol Rev 43:73–102, 1979) for the genus
Pseudomonas, Piggot and Hoch (Microbiol Rev 49:158 –179,
1985) forBacillus subtilis, Perkins et al. (Microbiol Rev 46:426 –
570, 1982) for Neurospora crassa, and Mortimer and Schild
(Microbiol Rev 49:181–213, 1985) for Saccharomyces cerevi-
siae. For yeasts, Chlamydomonas spp., and several fungal spe-
cies, symbols such as those given in the Handbook of Microbi-
ology, 2nd ed. (A. I. Laskin and H. A. Lechevalier, ed., CRC
Press, Inc., Cleveland, OH, 1988) should be used.
Conventions for naming genes. It is recommended that
(entirely) new genes be given names that are mnemonics of
their function, avoiding names that are already assigned and
earlier or alternative gene names, irrespective of the bacterium
for which such assignments have been made. Similarly, it is
recommended that, whenever possible, orthologous genes
present in different organisms receive the same name. When
homology is not apparent or the function of a new gene has not
been established, a provisional name may be given by one of
the following methods. (i) The gene may be named on the basis
of its map location in the style yaaA, analogous to the style used
for recording transposon insertions (zef) as discussed below. A
list of such names in use for E. coli has been published by Rudd
(Microbiol Mol Biol Rev 62:985–1019, 1998). (ii) A provi-
sional name may be given in the style described by Demerec et
al. (e.g., usg, gene upstream of folC). Such names should be
unique, and names such as orf or genX should not be used. For
reference, the E. coli Genetic Stock Center’s database includes
an updated listing of E. coli gene names and gene products. It is
accessible on the Internet (http://cgsc2.biology.yale.edu/index
.php). A list can also be found in the work of Riley (Microbiol
Rev 57:862–952, 1993). For the genes of other bacteria, consult
the references given above.
For prokaryotes, gene names should not begin with prefixes
indicating the genus and species from which the gene is de-
rived. (However, subscripts may be used where necessary to
distinguish between genes from different organisms or strains
as described in section v of “Bacteria,” above.) For eukaryotes,
such prefixes may be used for clarity when discussing genes
with the same name from two different organisms (e.g.,
ScURA3 versus CaURA3); the prefixes are not considered part
of the gene name proper and are not italicized.
Locus tags. Locus tags are systematic, unique identifiers
that are assigned to each gene in GenBank. All genes men-
tioned in a manuscript should be traceable to their sequences
by the reader, and locus tags may be used for this purpose in
manuscripts to identify uncharacterized genes. In addition, au-
thors should check GenBank to make sure that they are using the
correct, up-to-date format for locus tags (e.g., uppercase versus
lowercase letters and the presence or absence of an underscore,
etc.). Locus tag formats vary between different organisms and also
may be updated for a given organism, so it is important to check
GenBank at the time of manuscript preparation.
“Mutant” versus “mutation.” Keep in mind the distinc-
tion between a mutation (an alteration of the primary se-
quence of the genetic material) and a mutant (a strain carrying
one or more mutations). One may speak about the mapping of
a mutation, but one cannot map a mutant. Likewise, a mutant
has no genetic locus, only a phenotype.
“Homology” versus “similarity.” For use of terms that
describe relationships between genes, consult the articles by
Theissen (Nature 415:741, 2002) and Fitch (Trends Genet
16:227–231, 2000). “Homology” implies a relationship be-
tween genes that have a common evolutionary origin; par-
tial homology is not recognized. When sequence compari-
sons are discussed, it is more appropriate to use the term
“percent sequence similarity” or “percent sequence iden-
tity,” as appropriate.
Strain designations. Do not use a genotype as a name (e.g.,
“. . . subsequent use of leuC6 for transduction . . .”). If a strain
designation has not been chosen, select an appropriate word
combination (e.g., “another strain containing the leuC6 muta-
tion”).
Viruses. The genetic nomenclature for viruses differs from
that for bacteria. In most instances, viruses have no phenotype,
since they have no metabolism outside host cells. Therefore,
distinctions between phenotype and genotype cannot be made.
Superscripts are used to indicate hybrid genomes. Genetic
symbols may be one, two, or three letters. For example, a mu-
tant strain ofmight be designatedAam11 int2 red114 cI857;
this strain carries mutations in genes cI, int, and red and an
amber-suppressible (Am) mutation in gene A. A strain desig-
nated  att434 imm21 would represent a hybrid of phage  that
carries the immunity region (imm) of phage 21 and the attach-
ment (att) region of phage 434. Host DNA insertions into vi-
ruses should be delineated by square brackets, and the genetic
symbols and designations for such inserted DNA should con-
form to those used for the host genome. Genetic symbols for
phage  can be found in reports by Szybalski and Szybalski
(Gene 7:217–270, 1979) and Echols and Murialdo (Microbiol
Rev 42:577–591, 1978).
Eukaryotes. FlyBase (http://flybase.org/) is the genetic
nomenclature authority for Drosophila melanogaster.
WormBase (http://www.wormbase.org/#01-23-6) is the
genetic nomenclature authority for Caenorhabditis elegans.
When naming genes for Aspergillus species, the nomencla-
ture guidelines posted at http://www.aspergillusgenome
.org/Nomenclature.shtml should be followed, and the
Aspergillus Genome Database (http://www.aspgd.org/)
should be searched to ensure that any new name is not already
in use. The Saccharomyces Genome Database (https://www
.yeastgenome.org/) and the Candida Genome Database (http:
//www.candidagenome.org/) are authorities for Saccharomyces
cerevisiae and Candida albicans genetic nomenclature, respec-
tively. For information about the genetic nomenclature of
other eukaryotes, see the Instructions to Authors for Molecular
and Cellular Biology.
Transposable elements, plasmids, and restriction en-
zymes. Nomenclature of transposable elements (insertion se-
quences, transposons, and phage Mu, etc.) should follow the
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recommendations of Campbell et al. (Gene 5:197–206, 1979),
with the modifications given in section vi of “Bacteria,” above.
The Internet site where insertion sequences of eubacteria and
archaea are described and new sequences can be recorded is
https://www-is.biotoul.fr.
The system of designating transposon insertions at sites
where there are no known loci, e.g., zef-123::Tn5, has been
described by Chumley et al. (Genetics 91:639 – 655, 1979). The
nomenclature recommendations of Novick et al. (Bacteriol
Rev 40:168 –189, 1976) for plasmids and plasmid-specified ac-
tivities, of Low (Bacteriol Rev 36:587– 607, 1972) for F factors,
and of Roberts et al. (Nucleic Acids Res 31:1805–1812, 2003)
for restriction enzymes, DNA methyltransferases, homing en-
donucleases, and their genes should be used whenever possi-
ble. The nomenclature for recombinant DNA molecules, con-
structed in vitro, follows the nomenclature for insertions in
general. DNA inserted into recombinant DNA molecules
should be described by using the gene symbols and conven-
tions for the organism from which the DNA was obtained.
Tetracycline resistance determinants. The nomenclature
for tetracycline resistance determinants is based on the pro-
posal of Levy et al. (Antimicrob Agents Chemother 43:1523–
1524, 1999). The style for such determinants is, e.g., Tet B; the
space helps distinguish the determinant designation from that
for phenotypes and proteins (TetB). The above-referenced ar-
ticle also gives the correct format for genes, proteins, and de-
terminants in this family.
ABBREVIATIONS AND CONVENTIONS
Verb Tense
ASM strongly recommends that for clarity you use the past
tense to narrate particular events in the past, including the
procedures, observations, and data of the study that you are
reporting. Use the present tense for your own general conclusions,
the conclusions of previous researchers, and generally accepted
facts. Thus, most of the abstract, Materials and Methods, and Re-
sults will be in the past tense, and most of the introduction and
some of the Discussion will be in the present tense.
Be aware that it may be necessary to vary the tense in a single
sentence. For example, it is correct to say “White (30) demon-
strated that XYZ cells grow at pH 6.8,” “Figure 2 shows that
ABC cells failed to grow at room temperature,” and “Air was
removed from the chamber and the mice died, which proves
that mice require air.” In reporting statistics and calculations, it
is correct to say “The values for the ABC cells are statistically
significant, indicating that the drug inhibited . . . .”
For an in-depth discussion of tense in scientific writing, see
How To Write and Publish a Scientific Paper, 7th ed.
Abbreviations
General. Abbreviations should be used as an aid to the reader,
rather than as a convenience to the author, and therefore theiruse
shouldbe limited. Abbreviations other than those recommended
by the IUPAC-IUB (Biochemical Nomenclature and Related Doc-
uments, 1992) should be used only when a case can be made for
necessity, such as in tables and figures.
It is often possible to use pronouns or to paraphrase a long
word after its first use (e.g., “the drug” or “the substrate”).
Standard chemical symbols and trivial names or their symbols
(folate, Ala, and Leu, etc.) may also be used.
Define each abbreviation and introduce it in parentheses the
first time it is used; e.g., “cultures were grown in Eagle minimal
essential medium (MEM).” Generally, eliminate abbreviations
that are not used at least three times in the text (including
tables and figure legends).
Not requiring introduction. In addition to abbreviations
for Syste`me International d’Unite´s (SI) units of measurement,
other common units (e.g., bp, kb, and Da), and chemical sym-
bols for the elements, the following should be used without
definition in the title, abstract, text, figure legends, and tables:
DNA (deoxyribonucleic acid)
cDNA (complementary DNA)
RNA (ribonucleic acid)
cRNA (complementary RNA)
RNase (ribonuclease)
DNase (deoxyribonuclease)
rRNA (ribosomal RNA)
mRNA (messenger RNA)
tRNA (transfer RNA)
AMP, ADP, ATP, dAMP, ddATP,
and GTP, etc. (for the
respective 5 phosphates of
adenosine and other
nucleosides) (add 2-, 3-, or
5- when needed for contrast)
ATPase and dGTPase, etc.
(adenosine triphosphatase
and deoxyguanosine
triphosphatase, etc.)
NAD (nicotinamide adenine
dinucleotide)
NAD (nicotinamide adenine
dinucleotide, oxidized)
NADH (nicotinamide adenine
dinucleotide, reduced)
NADP (nicotinamide adenine
dinucleotide phosphate)
NADPH (nicotinamide adenine
dinucleotide phosphate,
reduced)
NADP (nicotinamide adenine
dinucleotide phosphate,
oxidized)
poly(A) and poly(dT), etc.
(polyadenylic acid and
polydeoxythymidylic acid,
etc.)
oligo(dT), etc. (oligodeoxy-
thymidylic acid, etc.)
UV (ultraviolet)
PFU (plaque-forming units)
CFU (colony-forming units)
MIC (minimal inhibitory
concentration)
Tris (tris[hydroxymethyl]
aminomethane)
DEAE (diethylaminoethyl)
EDTA (ethylenediamine-
tetraacetic acid)
EGTA (ethylene glycol-bis[-
aminoethyl ether]-N,N,N,N-
tetraacetic acid)
HEPES (N-2-hydroxyethyl-
piperazine-N-2-
ethanesulfonic acid)
PCR (polymerase chain reaction)
AIDS (acquired immuno-
deficiency syndrome)
Abbreviations for cell lines (e.g., HeLa) also need not be de-
fined.
The following abbreviations should be used without defini-
tion in tables:
amt (amount)
approx (approximately)
avg (average)
concn (concentration)
diam (diameter)
expt (experiment)
exptl (experimental)
ht (height)
mo (month)
mol wt (molecular weight)
no. (number)
prepn (preparation)
SD (standard deviation)
SE (standard error)
SEM (standard error of the mean)
sp act (specific activity)
sp gr (specific gravity)
temp (temperature)
vol (volume)
vs (versus)
wk (week)
wt (weight)
yr (year)
Drugs and pharmaceutical agents. Should an author de-
cide to abbreviate the names of antimicrobial agents in a man-
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uscript, the following standard abbreviations are strongly rec-
ommended.
(i) Antibacterial agents. Use the indicated abbreviations
for the following antibacterial agents.
amikacin (AMK)
amoxicillin (AMX)
amoxicillin-clavulanic acid
(AMC)
ampicillin (AMP)
ampicillin-sulbactam (SAM)
azithromycin (AZM)
azlocillin (AZL)
aztreonam (ATM)
carbenicillin (CAR)
cefaclor (CEC)
cefadroxil (CFR)
cefamandole (FAM)
cefazolin (CFZ)
cefdinir (CDR)
cefditoren (CDN)
cefepime (FEP)
cefetamet (FET)
cefixime (CFM)
cefmetazole (CMZ)
cefonicid (CID)
cefoperazone (CFP)
cefotaxime (CTX)
cefotetan (CTT)
cefoxitin (FOX)
cefpodoxime (CPD)
cefprozil (CPR)
ceftaroline (CPT)
ceftazidime (CAZ)
ceftazidime-avibactam (CZA)
ceftibuten (CTB)
ceftizoxime (ZOX)
ceftolozane-tazobactam (C/T)
ceftriaxone (CRO)
cefuroxime (axetil or sodium)
(CXM)
cephalexin (LEX)
cephalothin (CEF)
cephapirin (HAP)
cephradine (RAD)
chloramphenicol (CHL)
cinoxacin (CIN)
ciprofloxacin (CIP)
clarithromycin (CLR)
clinafloxacin (CLX)
clindamycin (CLI)
colistin (CST)
dalbavancin (DAL)
daptomycin (DAP)
dicloxacillin (DCX)
dirithromycin (DTM)
doripenem (DOR)
doxycycline (DOX)
enoxacin (ENX)
erythromycin (ERY)
fleroxacin (FLE)
fosfomycin (FOF)
gatifloxacin (GAT)
gentamicin (GEN)
grepafloxacin (GRX)
imipenem (IPM)
kanamycin (KAN)
levofloxacin (LVX)
linezolid (LZD)
lomefloxacin (LOM)
loracarbef (LOR)
meropenem (MEM)
methicillin (MET)
mezlocillin (MEZ)
minocycline (MIN)
moxalactam (MOX)
moxifloxacin (MXF)
nafcillin (NAF)
nalidixic acid (NAL)
netilmicin (NET)
nitrofurantoin (NIT)
norfloxacin (NOR)
ofloxacin (OFX)
oritavancin (ORI)
oxacillin (OXA)
penicillin (PEN)
piperacillin (PIP)
piperacillin-tazobactam (TZP)
polymyxin B (PMB)
quinupristin-dalfopristin
(Synercid) (Q-D)
rifabutin (RFB)
rifampin (RIF)
rifapentine (RFP)
sparfloxacin (SPX)
spectinomycin (SPT)
streptomycin (STR)
tedizolid (TZD)
teicoplanin (TEC)
telavancin (TLV)
telithromycin (TEL)
tetracycline (TET)
ticarcillin (TIC)
ticarcillin-clavulanic acid (TIM)
tigecycline (TGC)
tobramycin (TOB)
trimethoprim (TMP)
trimethoprim-sulfamethoxazole
(SXT)
trovafloxacin (TVA)
vancomycin (VAN)
(ii) -Lactamase inhibitors. Use the indicated abbrevia-
tions for the following -lactamase inhibitors.
avibactam (AVI)
clavulanic acid (CLA)
sulbactam (SUL)
tazobactam (TZB)
(iii) Antifungal agents. Use the indicated abbreviations for
the following antifungal agents.
amphotericin B (AMB)
anidulafungin (AFG)
caspofungin (CAS)
clotrimazole (CLT)
flucytosine (5FC)
fluconazole (FLC)
isavuconazole (ISA)
itraconazole (ITC)
ketoconazole (KTC)
micafungin (MFG)
nystatin (NYT)
posaconazole (POS)
terbinafine (TRB)
voriconazole (VRC)
(iv) Antiviral agents. Use the indicated abbreviations for
the following antiviral agents (for additional agents, refer to
Table 2 in De Clercq and Li, Clin Microbiol Rev 29:695–747,
2016 [https://doi.org/10.1128/CMR.00102-15]).
acyclovir (ACV)
cidofovir (CDV)
famciclovir (FCV)
foscarnet (FOS)
ganciclovir (GCV)
penciclovir (PCV)
valacyclovir (VCV)
zidovudine (AZT)
(v) Antimycobacterial agents. Use the indicated abbrevia-
tions for the following antimycobacterial agents.
bedaquiline (BDQ)
capreomycin (CAP)
clofazimine (CLO)
D-cycloserine (DCS)
delamanid (DMD)
ethambutol (EMB)
ethionamide (ETO)
isoniazid (INH)
para-aminosalicylic acid (PAS)
prothionamide (PTO)
pyrazinamide (PZA)
The use of “nonstandard” abbreviations to designate
names of antibiotics and other pharmaceutical agents gen-
erally will not be accepted, because the use of different ab-
breviations for a single agent has often caused confusion. If,
on occasion, a nonstandardized abbreviation for a drug or
pharmaceutical substance is used, it will be accepted under
the following conditions: (i) it must be defined at the first
use in the text, (ii) it must be unambiguous in meaning,
and (iii) it must contribute to ease of assimilation by
readers.
Chemical or generic names of drugs should be used; the
use of trade names is not permitted. Avoid the ambiguous
term “generation” when classes of drugs are described.
When code names or corporate proprietary numbers are to
be used, either the chemical structure of the compound or a
published literature reference illustrating the chemical
structure, if known, must be provided at the first occurrence
of the code name or number. For compounds not identified
by generic nomenclature, all previous or concurrent identi-
fication numbers or appellations should be listed in the
manuscript.
Pharmacodynamic terminology. Pharmacodynamic indi-
ces (PDIs) must be introduced at their first occurrence in the
text and follow guidelines set forth by Mouton et al. (J Anti-
microb Chemother 55:601– 607, 2005). In Materials and
Methods, it should be clearly stated how the PDIs were derived.
The most common indices used are the following: AUC/MIC ra-
tio (the area under the concentration-time curve over 24 h
in steady state divided by the MIC), AUIC (the area under
the inhibitory curve; note that the AUC/MIC ratio is not
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equal to the AUIC), %TMIC (the cumulative percentage of a
24-h period that the drug concentration exceeds the MIC
under steady-state pharmacokinetic conditions), Cmax/MIC
ratio (the peak level divided by the MIC), PTA (probability
of target attainment), and CFR (cumulative fraction of re-
sponse). Clear distinction should be made between %TMIC,
which is expressed as a percentage of the dosing interval,
and TMIC, expressed in hours. It is strongly recommended
that the prefix f be used with an index (e.g., fAUC) if the free,
unbound fraction of the drug is meant.
-Lactamases
Studies performed to characterize a -lactamase or the
interaction of a compound with a -lactamase (i.e., as a
substrate, inhibitor, or inducer) should follow the guide-
lines set forth by Bush and Sykes (Antimicrob Agents Che-
mother 30:6 –10, 1986). Assays that measure the hydrolysis
of -lactam antibiotics must be appropriate for the sub-
strate examined (e.g., iodometric methods are not appro-
priate quantitative assays for substrates whose products are
unknown). Reproducibility of results must be shown. When
referring to -lactamases, please use the functional designa-
tions defined by Bush and Jacoby (Antimicrob Agents Che-
mother 54:969 –976, 2010). Alternatively, if the amino acid
sequence for the enzyme is known, the -lactamases may be
described by molecular class as initiated by Ambler (Philos
Trans R Soc Lond B Biol Sci 289:321–331, 1980).
A database of defining amino acid alterations for many
-lactamases is maintained at https://www.ncbi.nlm.nih.gov
/projects/pathogens/submit_beta_lactamase/. The managers
of that site should be consulted about the name of a potentially
novel -lactamase sequence before a new designation or num-
ber is proposed for publication.
In Vitro Susceptibility Tests
Tabulate results of determinations of minimal inhibitory
and bactericidal concentrations according to the range of con-
centrations of each antimicrobial agent required to inhibit or
kill the members of a species or of each group of microorgan-
isms tested, as well as the corresponding concentrations re-
quired to inhibit 50 and 90% of the strains (MIC50 and MIC90,
respectively) and those required to kill 50 and 90% of the
strains (MBC50 and MBC90, respectively). Geometric mean
MICs may also be reported when relevant. The MIC50 and
MIC90 reported should be the actual concentrations tested that
inhibited 50 and 90%, respectively, of the strains. They should
not be values calculated from the actual data obtained. When
only six to nine isolates of a species are tested, tabulate only the
MIC range of each antimicrobial agent tested.
If more than a single drug is studied, insert a column labeled
“Test agent” between the columns listing the organisms and
the columns containing the numerical data and record data for
each agent in the same isolate order. Cumulative displays of
MICs or MBCs in tables or figures are acceptable only under
unusual circumstances.
The percentage of strains susceptible and/or resistant to an
antibiotic at its breakpoint concentration may be given only if
an appropriate breakpoint has been approved, as by the Clin-
ical and Laboratory Standards Institute (https://clsi.org/). In
the absence of approved breakpoints, authors cannot assign
breakpoints or use breakpoints from related antibiotics. An
exploratory analysis tabulating the percentage of strains inhib-
ited over a range of concentrations is acceptable.
Bactericidal tests must be performed with a sufficient in-
oculum (
5  105 CFU/ml) and subculture volume (0.01
ml) to ensure accurate determination of the 99.9% killing
endpoint, as described by Pearson et al. (Antimicrob Agents
Chemother 18:699 –708, 1980) and Taylor et al. (Antimi-
crob Agents Chemother 23:142–150, 1983). Inoculum size
and subculture volume are also critical to studies of combi-
nations of antimicrobial agents.
Synergy is defined in two-dimensional or checkerboard
tests when the fractional inhibitory concentration (FIC) or
fractional bactericidal concentration (FBC) index () is
0.5. In killing curves, synergy is defined as a 2-log10
decrease in CFU per milliliter between the combination and its
most active constituent after 24 h, and the number of surviving
organisms in the presence of the combination must be 2 log10
CFU/ml below the starting inoculum. At least one of the drugs
must be present in a concentration which does not affect the
growth curve of the test organism when used alone. Antagonism is
defined by aFIC orFBC of
4.0.
When standard twofold-dilution schemes are used to deter-
mine checkerboard interactions, the inherent variability of the
method casts doubt on the significance of interactions repre-
sented byFICs orFBCs of
0.5 but4. Therefore, such inter-
actions, if labeled at all, should be termed “indifferent.” Alterna-
tively, indices in this range may be described as “nonsynergistic”
or “nonantagonistic,” as appropriate. The technically imprecise
term “additive” should be avoided, as it is too easily misun-
derstood. See reports by W. R. Greco et al. (Pharmacol Rev
47:331–385, 1995), F. C. Odds (J Antimicrob Chemother
52:1, 2003), and M. D. Johnson et al. (Antimicrob Agents
Chemother 48:693–715, 2004) for further discussion of
these issues.
For killing curve tests, the minimal, accurately countable
number of CFU per milliliter must be stated and the method
used for determining this number must be described. In the
absence of any drug and with a sample size of 1 ml, this number
is 30 (1.5 in log10) CFU. If procedures for drug inactivation or
removal have not been performed, the author must state how
drug carryover effects were eliminated or quantified. For drugs
showing an inoculum effect, mere dilution below the MIC ob-
tained in standard tests is not sufficient.
Clinical Trials
(i) Registration. AAC requires the prospective registration
(i.e., before the first patient is enrolled) of a clinical trial in a
public trials registry in accordance with guidelines established
by the International Committee of Medical Journal Editors
(ICMJE) (http://www.icmje.org/recommendations/browse
/publishing-and-editorial-issues/clinical-trial-registration
.html). The ICMJE defines a clinical trial as “any research project
that prospectively assigns people or a group of people to an inter-
vention, with or without concurrent comparison or control
groups, to study the cause-and-effect relationship between a
health-related intervention and a health outcome.”
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AAC does not require registration in a particular registry,
but the registry chosen must meet the following criteria, in
agreement with ICMJE recommendations. It must be (a) ac-
cessible to the public free of charge, (b) open to all registrants,
(c) managed by a not-for-profit organization, (d) monitored
by a mechanism to ensure validity of registration data, and (e)
searchable electronically. A registration with missing fields or
uninformative terminology will be deemed inadequate.
The registry and the trial registration number must be in-
cluded at the end of the abstract. If a registration number is
available, the authors should state this number the first time a
trial acronym is used to refer to the trial being reported or to
other trials mentioned in the manuscript.
(ii) Criteria for enrollment. The methods used to find and
enroll patients and the criteria for enrollment in a clinical trial
should be stated. In addition, the time period (month/year to
month/year) of the enrollment should be specified. It should
be indicated, if appropriate, that written informed consent was
obtained and that the trial was approved by the pertinent com-
mittee on human subjects.
(iii) Method of randomization. Randomized, double-
blind studies are preferred. Comparisons using historical
controls are usually regarded as questionable unless the dif-
ferences in outcome between the groups are dramatic and
almost certainly the result of the new intervention. The ra-
tionale for the choice of the control group should be ex-
plained. The sample size should be justified, and the method
of randomization should be stated.
(iv) Criteria for determining whether a case is evaluable.
The minimum criteria for evaluability should be stated explic-
itly. For example, it should be stated that the minimum crite-
rion for evaluability was a or the combination of b and c rather
than a, b, and c without designating which were the minimum
criteria. The criteria for evaluability are usually different from
those for enrollment.
(v) Reasons for nonevaluability. State the number of pa-
tients in each group who were excluded from evaluation and
the reason(s) for each exclusion.
(vi) Criteria for assessment. Define each outcome for each
category of assessment (e.g., “clinical outcomes were classified as
cure, improvement, and failure; microbiological outcomes were
classified as eradication, persistence, and relapse”). The fre-
quency and timing of such assessments in relation to treat-
ment should be stated. Specify any changes made in the
study regimen(s) during the trial; the results for regimens
with and without such modification generally should be
stated separately. The criteria (questionnaires, results of
specific laboratory tests) for evaluation of adverse effects
should be stated, as should the period encompassed in the
assessment and the time of assessment in relation to the time of
treatment (e.g., daily during treatment). Some authors prefer to
consider superinfections as failures of treatment, whereas others
prefer to consider them separately or even as adverse effects. In
any event, the manuscript should state the number of superinfec-
tions with each regimen and should differentiate between super-
infections and colonization. The duration of follow-up should be
mentioned.
(vii) Statistical analyses. The type of statistical test should
be stated, and when appropriate, the reason for the choice of
test should be given. References should be given for statistical
procedures other than the t test, chi-square test, and Wilcoxon
rank sum test. The comparability of the treatment groups at
the baseline should be evaluated statistically.
For a review of some common errors associated with statis-
tical analyses and reports, plus guidelines on how to avoid
them, see the articles by Olsen (Infect Immun 71:6689 – 6692,
2003; Infect Immun 82:916 –920, 2014).
For a review of basic statistical considerations for virology
experiments, see the article by Richardson and Overbaugh
(J Virol 79:669 – 676, 2005).
(viii) Beta error. For trials which show no statistically
significant difference between regimens, calculate the prob-
ability () of a type II error and the power of the study
(1) to detect a specified clinically meaningful difference
in efficacy between the regimens. For further details, see the
article by Freiman et al. (N Engl J Med 299:690 – 694, 1978).
Alternatively, or in addition, indicate the magnitude of dif-
ference between the regimens that could have been detected
at a statistically significant level with the number of evalu-
able patients studied.
For further details, see the editorial on guidelines for clinical
trials (Antimicrob Agents Chemother 33:1829 –1830, 1989).
Reporting Numerical Data
Standard metric units are used for reporting length,
weight, and volume. For these units and for molarity, use
the prefixes m, , n, and p for 103, 106, 109, and 1012, re-
spectively. Likewise, use the prefix k for 103. Avoid compound
prefixes such as m or . Use g/ml or g/g in place of the
ambiguous ppm. Units of temperature are presented as follows:
37°C or 324 K.
When fractions are used to express units such as enzymatic
activities, it is preferable to use whole units, such as g or min, in
the denominator instead of fractional or multiple units, such as
g or 10 min. For example, “pmol/min” is preferable to
“nmol/10 min,” and “mol/g” is preferable to “nmol/g.” It is
also preferable that an unambiguous form, such as exponential
notation, be used; for example, “mol g1 min1” is prefera-
ble to “mol/g/min.” Always report numerical data in the ap-
propriate SI units.
Representation of data as accurate to more than two signif-
icant figures must be justified by presentation of appropriate
statistical analyses.
For a review of some common errors associated with statis-
tical analyses and reports, plus guidelines on how to avoid
them, see the articles by Olsen (Infect Immun 71:6689 – 6692,
2003; Infect Immun 82:916 –920, 2014).
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For a review of basic statistical considerations for virology
experiments, see the article by Richardson and Overbaugh
(J Virol 79:669 – 676, 2005).
Isotopically Labeled Compounds
For simple molecules, labeling is indicated in the chemical
formula (e.g., 14CO2, 3H2O, and H235SO4). Brackets are not
used when the isotopic symbol is attached to the name of a com-
pound that in its natural state does not contain the element (e.g.,
32S-ATP) or to a word that is not a specific chemical name (e.g.,
131I-labeled protein, 14C-amino acids, and 3H-ligands).
For specific chemicals, the symbol for the isotope
introduced is placed in square brackets directly preceding
the part of the name that describes the labeled entity. Note
that configuration symbols and modifiers precede the iso-
topic symbol. The following examples illustrate correct
usage:
[14C]urea
L-[methyl-14C]methionine
[2,3-3H]serine
[-14C]lysine
[-32P]ATP
UDP-[U-14C]glucose
E. coli [32P]DNA
fructose 1,6-[1-32P]bisphosphate
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